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Scars, including keloid and hypertrophic scars, are a common and unpleasant cosmetic and 
sometimes functional side effect of burn injury, trauma or surgery. Moisturising is one of the most 
common scar management techniques recommended by health professionals. Many clinicians 
believe that moisturiser application to scars can hydrate, reduce itch and increase pliability. Since 
trans-epidermal water loss (TEWL) is thought to be the mechanism of action behind the 
effectiveness of silicone gel sheeting/contact media, it may be that moisturisers also impact on 
TEWL to have an effect on scars. Some moisturisers also contain additional ingredients, such as 
vitamins or pharmaceuticals, which may also have an effect on scars. This systematic review aims 
to assess the effect of moisturisers on scars, excepting atrophic scars. The aim is to present 
recommendations that are relevant and useful to consumers and clinicians.  
Method 
Databases searched were PubMed, CINAHL, Embase and Web of Science. Critical appraisal was 
conducted using Joanna Briggs Institute (JBI) tools. The search located 33 studies of low quality 
and high risk of bias and these were selected for inclusion: 14 RCTs, 11 quasi-experimental, seven 
case series and one case report. Overall there were 867 participants or scars included in the review. 
Data on the outcomes reported by the included studies was extracted using JBI tools.  
A subset of seven studies, including a total of 82 keloids, examining the outcome of recurrence of 
keloids post-excision and application of Imiquimod cream was subjected to a meta-analysis utilising 
StatsDirect software (Cambridge, UK) and the random effects model. In an attempt to determine if 
the location of the keloid or the excision method and resultant method of healing (primary closure 
versus healing by secondary intention) impacted these results, subgroup analysis was performed.  
Narrative synthesis was performed on the results of the remaining 26 included studies. The 
subjective nature of outcome/scar measurement was noteworthy. Despite the variable quality of the 
studies, all were included so as to provide a current view of the state of the evidence. Outcomes 
addressed in the narrative synthesis included cosmesis, scar parameters, itch and pain, TEWL and in 
vitro outcomes. 
Results 
Thirteen moisturisers were examined for their effects on cosmesis. Moisturisers that were reported 
to have statistically significant positive effects on cosmesis included Lumiere Bio-Restorative Eye 
Cream, Tretinoin, Scarguard® and Cetaphil®. Imiquimod was the only moisturiser found to have a 
statistically significant detrimental effect on cosmesis. Studies examining 18 different moisturisers 
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reported on scar parameters. Of these, those that reported a statistically significant effect on scar 
parameters were Imiquimod, Aquaphor®, Mederma®, Scarguard® HSE (hydrocortisone, silicone, 
vitamin E), Cetaphil®, Tretinoin, Eucerin®, Putrescine, Keratin Gel and Doxepin. Eight 
moisturisers were examined for their effects on itch and pain; statistically significant benefits on 
both outcomes were observed with Doxepin, Provase®, Mugwort lotion and Eucerin®. Only one 
study examined TEWL as an outcome measure and found Alhydran to have a statistically 
significant positive effect. Considering in vitro outcomes, only one moisturiser, Dermovate, did not 
have a statistically significant effect, whereas the others, Tretinoin, Wubeizi ointment and 
Imiquimod, did.  
Seven studies, examining a total of 82 keloids, investigated their recurrence post excision and 
application of Imiquimod. The similarity in design allowed for statistical meta-analysis. Meta-
analysis revealed a recurrence rate of 39% following application of Imiquimod post scar excision. 
This result however was imprecise (95% CI = 8.4% to 74.4%) and the analysis showed significant 
statistical heterogeneity (I2 =87.5%, 95% CI = 75.7% to 92.2%). The use of primary excision and 
bilayer closure or shave/tangential excision did not alter the outcome as compared to when all 
studies were examined together. When analysis was conducted based on the location of the keloid 
scar, earlobe keloids had a recurrence rate of 5.4% (95% CI = 0% to 21.7%), (I2 = 52.9 %, 95% CI 
= 0% to 82.6%). Remaining keloids excised were predominantly on the trunk and their recurrence 
rate was higher, at 76.8% (95%CI = 36.1 to 100%), (I2 = 70.5%, 95% CI = 0% to 86.4%). Many of 
the included studies reported adverse events especially erythema and crusting resulting in a rest 
period at the two to three week mark.  
Discussion 
Considering the results of this review and the availability and costs of the moisturisers investigated, 
recommendations are provided for practice. Costly and prescription moisturisers should be selected 
for application to scars appearing in small and/or cosmetically sensitive areas, such as the face. 
Clinicians managing scars covering a large surface area should consider readily available, low cost 
moisturisers that show some evidence of effectiveness.  
Of those classified as prescription only, based on their availability in Australia, only Doxepin and 
Putrescine can be recommended, but with reservations. For high cost, over the counter moisturisers, 
Tretinoin, Wubeize, Lumiere Bio-Restorative Eye Cream, Scarguard® HSE, Provase and Mugwort 
Lotion can be recommended, but with reservations. Only Alhydran can be recommended with any 
confidence. The low cost, over the counter moisturisers that can be recommended with reservations 
are Eucerin® and Cetaphil®.   
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Use of subjective scales far outweigh the use of objective instrumentation among relevant studies. 
Future research needs to utilise appropriate and available instrumentation in the measurement of 
outcomes. As the included studies in the narrative synthesis group examined keloid and/or 
hypertrophic scars, recommendations for specific scar types cannot be provided. Some studies also 
utilised linear scars, which are commonly normotrophic and therefore were likely to have been 
resolved without any intervention.   
Further research is required to examine the effects of basic moisturisers that are regularly in use and 
readily available to the general public. A small number of these were included in studies as control. 
It is not known if these moisturisers are just as effective, if not more, than those that are costlier and 




This chapter presents information regarding how this systematic review was conceptualised 
and why it is needed. This chapter also provides some background information to outline the 
different structures of the skin and how these are affected in wound healing and scar 
formation. The concepts of trans-epidermal water loss (TEWL), hydration and occlusion and 
how this is important in scar management are addressed. Different scar types and their unique 
characteristics are addressed in this chapter. In addition to moisturiser application there are 
other accepted strategies to manage scars which are often prescribed at the same time as 
moisturisers and these are also introduced. Since moisturisers are available as many 
formulations, a brief description of their characteristics is provided and an attempt to group 
them according to their relevance to clinicians and consumers has been outlined. The science 
of evidence synthesis introduces evidence based practice and the Joanna Briggs Institute 
(JBI) model. 
 
1.1 Context of the review 
Following burns, trauma or surgery, after immediate life and wound salvaging procedures are 
undertaken, a priority for the health professional is management of the scars that begin to 
form. Burns, trauma and all forms of surgery can cause scars that can become problematic. 
Scars classified as hypertrophic or keloid are particularly problematic.1 These types of scars 
impact upon physical function by causing restrictions to movement and contractures, and can 
be overly sensitive and itchy.2 Furthermore, they can adversely affect the psychosocial 
recovery of individuals by affecting the way they perceive their body image and how they 
feel others perceive them (cosmesis), and they can be a reminder of the trauma that had 
caused their scars.3 Overall, scars can influence the quality of life of those that bear them. 
Therefore, the correct management of scars is of utmost importance.4  
Health professionals that work extensively with scars commonly recommend pressure, 
contact media and massage as there is evidence to support this composite approach.1 In 
addition to these scar management practices, moisturising is also recommended. It is 
commonly believed that contact media and moisturisation hydrate the scar and as a result 
reduce scar activity.5  
Despite the accepted practice of applying moisturisers to scars, there is little consensus or 




1.2 The need for this systematic review 
A recent systematic review (that was conducted by a group including this author) assessed the 
effects of moisturisers on scars resulting exclusively from burn injury.6 However, as the 
inclusion criteria included only burn scars, only one eligible study was located.6 Considering 
the results of the systematic review and in an attempt to establish international practice, this 
author then conducted a survey across Australia, New Zealand, Canada and the United States 
of America among burn therapists on what moisturisers they would recommend to their 
patients and why.5  
The survey revealed that 53 therapists recommended 29 different moisturisers. Responses 
reflected the belief that moisturisers hydrate scars, with 85% of responders reporting this as 
the reason for recommending moisturisers. Recommendations for specific moisturiser use 
were most commonly aligned to the properties of the moisturiser and facilitation of massage. 
However, when the respondents were asked if they were able to cite evidence regarding their 
choice of moisturiser, only one could provide a reference.5 
Due to the absence of collated research within the burns field it was decided that a systematic 
review that investigated and included research beyond burns treatment and management may 
provide the evidence necessary to inform the practice of clinicians working with scars in 
general. A search of PubMed, Cochrane and JBI revealed that, apart from the above 
systematic review on burn scars6, there were no systematic reviews on this topic.   
 
1.3 Skin and scar formation 
1.3.1 Skin 
The skin is the heaviest organ in the human body, comprising about 16% of dry mass. Its 
function is to maintain the physiological barrier between our internal milieu and the outside 
environment, but its other functions are numerous. The skin consists of three layers: the 
epidermis, dermis and subcutaneous tissue or panniculus.7 The epidermis consists 
predominantly of cells (keratinocytes) which, as their name indicates, synthesise keratin 
which forms part of the waterproofing function of skin.7 The most superficial layer of the 
epidermis, consisting of the dead keratinocytes, is called the stratum corneum. Scars have a 
thinner, and therefore malfunctioning, stratum corneum which results in increased TEWL.8 
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The dermis is a molecular structure and holds the functional structures such as hair follicles, 
sebaceous glands and sweat glands (although these are epidermal in origin), and is 
fundamentally made up of Type 1 collagen.7 Fibroblasts are responsible for producing this 
collagen and are the cells responsible for scar production in the latter stages of wound healing 
after trauma to the dermis.  
 
1.3.2 Wound healing and scar formation 
When an injury occurs to the skin, a series of events begins instantaneously. The dermal 
component of wound repair is typically divided into four phases: coagulation, inflammatory 
response, granulation tissue formation and matrix remodelling.9 It is in the final stage, matrix 
remodelling, where scar formation is considered to begin and the scar can be termed an active 
scar until this phase is complete. It is at this point that the scar is deemed to be mature. 
Scarring of other non-dermis mesodermal derivatives, such as connective tissues, muscle and 
tendon, for example, were excluded from this review as scarring of these structures is a 
different phenomenon.  
The formation of a scar (also known as a cicatrix) is a normal healing response to a deep 
wound in the skin. Deep wounds that result in damage to the dermis will ‘scar’ and it is 
unlikely that there are adults who cannot locate a scar on their body. Despite this, most adults 
would not have a scar significant enough to lead to life changes or emotional distress. For 
those that do, however, the scar may also have other physical complications. The prevalence 
of contractures, for example, has been reported in a systematic review of burn scars to vary 
between 38% and 54%.10  
The longer the phase of inflammation, the more likely a scar will form; time to healing is 
dependent on how deep the wound is.11, 12 Acknowledgement of this relationship has led to 
guidelines that outline that if a wound takes longer than 14-21 days to heal it will require scar 
management to minimise the detrimental effects of hypertrophic scar.13  
 
1.3.3 Trans-epidermal water loss, hydration and occlusion: its relationship to scar formation 
As also mentioned above (section 1.3.1) the stratum corneum of scars is thinner and therefore 
the normal barrier function of the skin involved is compromised. This results in higher than 
normal TEWL and the underdeveloped stratum corneum is unable to retain optimum water 
levels, which is termed hydration.14 When this occurs, keratinocytes produce inflammatory 
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cytokines that signal the fibroblasts to produce excessive amounts of collagen in an attempt to 
aid water retention of the stratum corneum.14, 15  
It is hypothesised that the effect of silicone gel sheets is to return the TEWL to homeostasis at 
the scarred area. They have an effect of partial occlusion which normalises the upregulated 
scar formation caused by the increase in TEWL.14 After application of moisturisers, the water 
content of the stratum corneum (the outermost layer of the skin) is increased, filling the 
spaces between partially desquamated skin flakes, making the skin smoother to touch.16 It is 
for these reasons that clinicians commonly recommend moisturisers for hydration of a scar.5 
It has been observed that a wound that has healed by secondary intention (a wound that has 
taken longer than 21 days to heal) and has formed a hypertrophic scar has a higher rate of 
TEWL than a wound that has been primarily closed, i.e. by skin graft.17 In addition, keloid 
scars have an even higher rate of TEWL than other hypertrophic scars.18 Hydration of the 
scar can be measured with an instrument called a Corneometer®, and TEWL can be 
measured with a Tewameter®, such as that by utilised by Hoeksema et al (2013).19  
 
1.4 Types of scars   
In their meta-analysis of scar prevention and treatment, Mustoe et al. (2002)1 defined a 
classification system based on appearance and activity to assist with scar terminology. Scars 
were classified as linear hypertrophic (e.g. surgical/traumatic) or widespread hypertrophic 
(e.g. burn), minor keloid or major keloid and mature or immature (which can apply to any 
scars).1 This classification system does not include atrophic scars. The recommendation is 
that if no hypertrophy occurs within three months, scar prevention measures can be ceased.13  
 
1.4.1 Linear scars 
Linear scars are those that are formed typically following surgery where the edges of the 
deeper sections of the wound are primarily closed. Therefore, the wound healing is by 
primary intention and results in a flat linear scar. This is likely due to rapid healing, within 
one to two weeks, which generally precludes hypertrophic scarring.11, 12  
If there are intrinsic factors (foreign bodies, infection, bleeding, tension, etc.) or extrinsic 
factors (malnutrition, pharmaceutical agents, co-existing disease, etc.), the phase of 
inflammation is prolonged. The proliferation of collagen in the proliferative phase is 
excessive and the resulting scar becomes hypertrophic. While no evidence documenting the 
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incidence of hypertrophy in these types of scars is available, clinically, they have been 
observed to rarely progress to a hypertrophic scar that requires ongoing management. 
 
1.4.2 Hypertrophic scars 
Formation of a hypertrophic scar indicates there has been damage or trauma to the deeper 
(dermal) layer of the skin which contains structures such as sweat glands, hair follicles and 
associated oil glands.20 A common observation of burn patients, who have extensive areas of 
hypertrophic scarring, is the subsequent failure to sweat or produce oils from their scars as a 
result of the loss of sweat and oil glands in the skin, which contributes to dry scars.21  
The reported incidence of hypertrophic scarring after burn injury varies from 32% to 72%.22 
As suggested by its name, a hypertrophic scar is raised above the normal level of the skin but 
remains within the confines of the original wound. Their course is to generally increase in 
activity for the first six months, then decrease in activity until final maturity at around 18 
months post injury.23 Hypertrophic scars commonly arise from extensive wounds that are left 
to spontaneously heal (also termed healing by secondary intention) and where wounds are 
managed by skin grafting (primary closure or primary intention healing).24 These subgroups 
of hypertrophic scars show different characteristics, one of which is the rate of TEWL.17 
Spontaneously healed scars have a higher rate of TEWL than skin grafted scars, and both 
have a higher TEWL than normal skin.17  
Risk factors for more aggressive scarring include darker skin, female gender, site on the body 
(neck, chest), younger in age, longer time to healing and severity (e.g. depth) of injury.22 
Hypertrophy is a result of a local inflammatory process where the skin’s immune system 
maintains a continuous inflammatory activated state in the hypertrophic tissue.25 Females 
tend to have a higher risk for diseases of immunologic pathogenesis (e.g. arthritis) and this 
may be the reason for their higher risk of hypertrophic scarring.25 People who are younger 
have more functional immune systems than those who are older and stronger anabolic basal 
activity that increases the remodelling phase of wound healing.25 The location of the scar in 
regions that are regularly under tension and movement tend to contract more due to higher 
levels of myofibroblasts, and these scars tend to become bigger to accommodate the higher 
tension in the skin.25 When there is a deeper wound and subsequently increased delay in 
reepithelialisation, there is a prolonged inflammatory phase and subsequent increase in the 




1.4.3 Keloid scars 
Keloid scars can be readily differentiated from hypertrophic scars. Unlike hypertrophic scars, 
they extend beyond the border of the original injury, have a longer course of activity, and 
have different pathophysiology and genetic factors.26 Collagen production is increased 20-
fold in a keloid scar and three-fold in a hypertrophic scar compared to normal unscarred 
skin.27 The collagen in hypertrophic scars maintains a wavy pattern parallel to the epidermis 
whereas in keloids the collagen takes on a more random pattern.28 There is a difference 
between the immunophenotypical profiles of keloidal and hypertrophic scar tissue, 
particularly, the major histocompatibility complex (MHC) genes.29 It is unlikely that a single 
gene is responsible.29 Interaction between gene pathways and environmental factors is likely, 
since not every scar in the one individual will become a keloid.29 Keloidal scar tissue has a 
more prolonged inflammatory period with immune cell infiltrate present which may explain 
why keloid scars extend beyond the border of the original wound, while in hypertrophic scars 
the immune cell infiltrate decreases over time.29   
People with keloids have reduced levels of interferon production.30 Jacob et al.(2013)31 found 
that genes whose expression is associated with apoptosis are altered by Imiquimod (a 
prescription cream that acts as immune response modifier) and the authors suggest that the 
keloid tissue may move toward a more normalised phenotype rather than the continued 
aberrant expression. They also have a high rate of TEWL, and have been measured as having 
a higher TEWL than hypertrophic scars.18 
Factors that play a major role in keloid development are a genetic predisposition as darker 
skinned individuals are 15 times more likely to develop a keloid scar.32 Another significant 
factor in keloid formation is skin tension when surgical incisions extend beyond relaxed skin 
tension lines.32 However, hypertrophic scars are also exacerbated by high tension. Keloids 
also develop more readily during and after puberty, recede at menopause, and are enlarged 
during pregnancy.32 Locations of keloids are predominantly on the ear lobe, shoulders and 
sternal notch/anterior chest.32  
 
1.4.4 Atrophic scars 
Examples of atrophic scars are those that arise from acne or chickenpox.33 Atrophic scars 
have a different pathophysiology to hypertrophic and keloid scars, and perhaps this is the 
reason for them not being included in Mustoe et al.’s (2002)1 classification of scars. Atrophic 
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scars are likely related to enzymatic degradation of collagen fibres and subcutaneous fat 
which support the overlying skin.34 Considering that atrophic scars can occur from 
degradation of collagen but keloid and hypertrophic scars are associated with excess 
collagen, the resulting treatments are quite different.  
 
1.5 Scar management 
Scar management becomes a vital component of the treatment plan for clinicians treating 
those who acquire a hypertrophic or keloid scar. This is especially so in the field of burns, an 
injury which predominantly affects the skin and results in extensive hypertrophic scarring. 
The most commonly utilised and accepted conservative treatments to minimise the activity of 
scars are pressure therapy,35 contact media (typically silicone gel),36 massage and skin care 
(moisturising, sun protection and management of folliculitis).21 Pressure therapy is commonly 
implemented with the use of pressure garments and contact media is commonly implemented 
with the use of silicone gel sheets.21 Treatment of scars to maximise function and their final 
cosmetic appearance occurs while the scar is immature.1 Once the scar is mature, it is no 
longer re-modelling and scar management is no longer considered effective.1  
While there is evidence that scar massage has a positive effect on scars the evidence suggests 
it is less effective than the use of pressure or contact media.37 Scar massage or soft tissue 
mobilisation (STM) facilitates the scar in returning to normal skin properties.38 Scar massage 
alters the scar tissue matrix by breaking the strong bonds between the collagen fibres and by 
moving the interstitial fluid.38 Cho et al.(2014)39 found that massage in conjunction with 




Moisturisers can come in many forms, including creams, ointments, unguents, pastes, oils, 
lotions and salves. Creams are the most common and are usually emulsions of oil-in-water.16 
Lotions are usually less viscous than creams and have a lower oil content than creams.16 
Typical ingredients in moisturisers (in order of highest to lowest amounts) include water, oils, 
emulsifiers and preservatives.16 Other ingredients for enhancement of biological effects or 
consumer acceptance include humectants, silicones, herbal extracts, fragrance, antioxidants 
and chelators.16 Water immediately hydrates the stratum corneum but is short lived as it 
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quickly evaporates if not retained by the active chemical ingredients in the moisturiser.40 
Humectants increase the amount of water held by the stratum corneum, and moisturisers with 
humectants are superior for the treatment of dry skin disorders compared to those without 
humectants.40 Glycerol is the most common humectant.16 Others include propylene glycol, 
butylene glycol, panthenol, 2-pyrrolidone-5-carboxylic acid (pidolic acid), alpha-hydroxy 
acids (AHA), and urea.16 However, propylene glycol is a known allergen and is found in 20% 
of moisturisers.41 Fragrances and preservatives are the main sensitisers causing adverse 
reactions attributable to moisturiser use.16 Despite this, fragrances are found in almost 70% of 
moisturisers and parabens (a preservative) are found in over 60% of moisturisers.41  
As use of moisturisers results in increased hydration of the stratum corneum, the swelling of 
the desquamated cells may result in an occlusive effect; it has been proposed15 that occlusion 
at the stratum corneum acts to down-regulate the pro-fibrotic signalling to the fibroblasts 
within the dermis.8 Therefore, the mechanism of action of moisturisers is not only more 
complicated than simply ‘hydrating’ the skin but also has a cascading effect on the deeper 
scar tissue activity.  
 
1.6.1 Characterising moisturisers by type and availability 
When burn clinicians were asked why they recommended a moisturiser, the foremost general 
property was to facilitate massage.5 Beyond that, clinicians recommended moisturisers as 
they were easy to find or were a known brand, long lasting and at a low cost or were readily 
available.5 Therefore, when scrutinising all the products included in this systematic review it 
is clinically useful to categorise them according to their availability. For example, low 
volume, high cost products would be suitable for cosmetically sensitive, small facial scars. 
Alternatively, high volume, low cost moisturisers would be most suitable for extensive 





Table 1-1: Australian availability to consumers of products examined in this systematic 
review  
Availability Product 
Prescription – high cost, 
low volume, high 
potency ingredients.  
Imiquimod (immune modulator) 
Tacrolimus ointment (immune modulator) 
Doxepin (anti-histamine) 
Putrescine/Fibrostat (effect on collagen) 
Clobetasol proprionate 0.05%/Dermovate (corticosteroid) 
Aristocort® (corticosteroid) 
High cost over the 
counter – small volume, 
limited availability e.g. 
10-30millilitre tube.  
Tretinoin/retinoic acid 0.05%/vitamin A 
Bio-Oil® 
Wubeizi (only available in China) 
Lumiere Bio-Restorative Eye Cream 






Low cost over the 
counter – large volume 
e.g. 1-2litre.  
Vitamin E creams 
Cetaphil® 






1.6.1.1 Prescription/Medicated Moisturisers 
Prescription creams, as categorised in this review, are those that tend to be available in 
Australia only by prescription from a medical practitioner and contain high potency 
ingredients; as a result, they tend to also be high cost and come in small tubes. Therefore 
these moisturisers are not generally suitable for extensive, large surface area scars, but rather 
for small, problematic or cosmetically unappealing scars. The table below outlines the cost of 
the each of the creams in this category, demonstrating that they can vary from AUD$1 to just 





Table 1-2: Cost and usual available sizes of prescription only creams 
Cream Available size Cost:  
AUD/gram 
Imiquimod 5%  3g 20 
Tacrolimus ointment 30g 8.10 
Doxepin/Prudoxin 45g 7.27 
Putrescine (Fibrostat®) Not available - 
Clobetasol proprionate 0.05%/Dermovate  15g 3.05 
Aristocort® 0.1% 90g 1.16 
Prices obtained by basic internet searching in January 2018 
 
Imiquimod 5% 
Imiquimod 5% cream is an immune response modifier that is commonly utilised to treat 
genital warts. It is capable of inducing IFN-α, TNF-α and interleukins 1, 6 and 8.30 A 
systematic review has examined the effect of Imiquimod on recurrence rates of keloids post 
excision.42 Four studies on Imiquimod were analysed and they estimated the overall 
recurrence rate to be 24.7% (95% CI, 3.2-76.4) and in a subgroup of earlobe scar recurrence, 
the rate was estimated to be 13.6% (95% CI, 4.3-35.5).42 The authors claimed that this 
recurrence rate was ‘better than expected’ as routine treatment results in ‘at least 
approximately 50%’.42 However, this 50% recurrence rate was obtained from only one study, 
albeit a large one, which was published in 1974, with earlobe only keloid excisions occurring 
from 1932 to 1970.43 The other referenced study reported recurrence rates of facial keloids 
that had been excised and treated with a steroid but had no data on untreated excised 
keloids.44 Considering that our current systematic review could not find reliable reports of a 
standard recurrence rate of keloids post excision, the rate of recurrence without post-
operative treatment is unclear.   
Tacrolimus ointment 
Tacrolimus ointment contains a drug that has an effect on tumour necrosis factor, TNF-α. The 
tacrolimus binds to a molecule involved in cellular growth and metabolism, and inhibits the 
expression of TNF-α which is a profibrotic (pro scarring) cytokine, i.e. it inhibits the process 




Doxepin hydrochloride (HCl) is used for clinical depression but it has also been found to 
have histamine receptor blocking properties.46 Doxepin HCl is available in a fivepercent 
cream – Prudoxin®.46 Doxepin has been found to be more potent than some antihistamines in 
studies examining common dermatological disorders.46 
Putrescine (Fibrostat®) 
Putrescine is a polyamine that is produced in the breakdown of amino acids in living and 
dead organisms and is responsible for the foul odour of putrefying flesh.47 Despite its 
interesting origin, it has previously been shown in vitro to inhibit extracellular type III 
collagen crosslinking – the collagen that is found elevated in hypertrophic scars.48 
Clobetasol proprionate 0.05% /Dermovate 
Dermovate is a topical corticosteroid containing the active ingredient clobetasol 
proprionate.49 Corticosteroids aim to reduce the production of collagen.49 Dermovate is 
considered to be ’Class 1 (super-potent)’ in the potency rankings of topical steroid 
preparations.50 However, the raft of atrophic changes in the skin causing thinning of the 
epidermis and dermis would likely be counterproductive when a scar already has a thinner 
stratum corneum (epidermis) than normal skin.50  
Aristocort® 0.1% 
As with Dermovate, Aristocort® A 0.1% (triamcinolone acetonide) potentially has all the 
side effects mentioned of a topical corticosteroid, but in comparison it is considered less 
potent ‘Class 3 (potent)’.50 
1.6.1.2 High cost, over the counter moisturisers 
For this review, moisturisers available to the consumer from a pharmacy over the counter for 
a ‘high cost’ and contain some form of ‘active ingredient’ are arranged in their own category. 
They are generally available in small tubes similar to prescription only items. As such, they 
are not suitable for extensive, large body surface area scars, but instead for small, problematic 
or cosmetically unappealing scars. Table 1-3 outlines the cost of each of the creams in this 





Table 1-3 Cost and usual available size of high cost over the counter creams. Prices 
obtained by basic internet searching in January 2018. 
Cream Available size Cost: AUD/gram 
or mL 
Tretinoin cream/retinoic acid/vitamin A (0.05%)  50g 1.09 
Bio-Oil® 60-200mL 0.17 
Wubeizi Not available  
Lumiere Bio-Restorative Eye Cream 15mL 6.27 
Mederma®/onion extract 50g 1.83 
Scarguard®/HSE 15g 2.30 
Keratin gel/KeragelT® 20g 20.65 
Provase® 59g 0.30 
Mugwort Lotion Not available  
Alhydran 250mL 0.82 
Prices obtained by basic internet searching in January 2018 
HSE: hydrocortisone, silicone, vitamin E 
 
Moisturisers containing Vitamin A (Tretinoin/retinoic acid) perhaps belong in the 
prescription only moisturisers (Section 1.6.1.1) as the 0.05% concentration is only available 
by prescription in Australia, however, there are many moisturisers claiming to contain 
vitamin A, retinoic acid, or its less potent variant retinol, over the counter. However, vitamin 
A containing moisturisers require additional precautions; in particular, it is only to be used at 
night as it thins the stratum corneum, making the skin more susceptible to sun damage, it 
needs to be used for three to six months to achieve epidermal changes and nine to 12 months 
to see dermal changes, and permanent changes may not occur as discontinuation will cause 
regression of clinical gains.51 
Bio-Oil® is a very well marketed product within Australia. Clinically this author has 
observed that patients with scars frequently ask about Bio-Oil®, have used it, or report that a 
concerned friend has recommended it. According to the Bio-Oil® website, it has a 
combination of plant extracts and vitamins suspended in an oil base.52 The ingredients list 
includes four different ‘botanicals’ (calendula, lavender, rosemary, chamomile), an ‘oil base’ 
which consists of eight different ingredients too extensive to examine in detail for the purpose 
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of this review, 13 different ‘fragrance’ ingredients, a colour and ‘vitamins’ A (retinyl 
palmitate) and E (tocopheryl acetate).53   
Mederma® is a gel containing a botanical extract allium cepa (onion extract) as the active 
ingredient. However, studies examining the effects of Mederma® provided insufficient 
descriptions as to which of the range of scar products advertised on the website were 
utilised.54  
Alhydran is an oil in water emulsion consisting of mostly aloe vera gel, mineral oil, decyl 
oleate, sorbitan stearate, propylene glycol, jojoba oil, and vitamins A, C, E and B12.19 
Alhydran was only previously available in Europe and has only recently (as of May 2018) 
become available in Australia. An exact price is yet to be provided but it is anticipated to be 
available in pharmacies at a higher cost than the basic moisturisers (Section 1.6.1.3).  
Moisturisers can be manufactured from other plant extracts such as the Wubeizi ointment 
which contains the ingredient Wu Bei Zi, a tannin produced by a tree following infestation by 
aphids. The mugwort lotion in the study by Ogawa and Ogawa (2008)55 consisted of 
mugwort extract (from the leaves and branches of Artemisia yomogi) methanol, ethanol and 
distilled water. It is reported that mugwort extract has biologic effects such as anti-histamine, 
anti-oxidant, induces apoptosis and has an anti-inflammatory effect.55 Information on the cost 
of this Chinese herb was difficult to find as it can come in a raw form and is then added to 
other ingredients to make up an ointment or cream.  
Scarguard® reportedly contains 0.5% hydrocortisone, silicone and Vitamin E.56 However, 
details about this product are unavailable on the internet and therefore it is suspected to be 
unavailable. Keratin has a role in epithelium differentiation, mechanically stabilising this 
layer against mechanical stress and maintaining hydration by providing a waterproof 
barrier.57 Keratin gel products have been predominantly studied with regards to wound 
healing and have shown positive results but there is only one study on the effect of a keratin 
gel on scar progress.57 
Provase® is a water and petroleum blend based moisturiser with 2% dimethicone and a blend 
of proteases. In vitro assays have shown that proteases work to degrade proinflammatory 
substances such as tumour necrosis factor-α, interleukin 6 and its receptor and matrix 
metalloproteinases.58 This product has been previously used to resolve inflammation and itch 





1.6.1.3 Low cost, over the counter moisturisers 
For this review, moisturisers that tend to be typically available to the consumer from 
convenience stores are categorised as low cost, over the counter moisturisers. Moisturisers in 
this category tend to be available in larger volumes such as 250mL to greater than 1L 
containers. Vitamin E creams, for example, can be as cheap as AUD3 for 1L, representing a 
cost of 0.3 cents per mL. Aquaphor®, Cetaphil® and Eucerin® are the most costly of this 
low cost group, costing around 2-4cents per mL. They therefore tend to be suitable for 
extensive scars covering large surface areas. 
Vitamin E, or its form alpha-tocopherol, which is the only form maintained in the human 
body, acts as an antioxidant protecting cells from oxidative stress.59 Since its discovery as the 
major lipid-soluble antioxidant in the skin, it has been used for treating many skin 
conditions.59 Curran et al. (2006)59 conducted a survey of 208 medical staff and students at 
their institution in Dublin, Ireland on their use and understanding of Vitamin E. They found 
that 68% of respondents thought that Vitamin E could be of use in improving the cosmetic 
appearance of scars, 25% recommend Vitamin E to patients to improve the cosmetic outcome 
but only 40% were aware of its biological function.59 In contrast, this author’s own survey of 
therapists from US, Australia and Canada found that three out of the 53 responders (6%) 
recommended vitamin E for scars.5  
Cetaphil® Moisturizing Lotion (Galderma Laboratories, LP Forth Worth, TX, USA) was 
included in one study56 as a placebo cream. There is a broad range of products under the 
name of Cetaphil®, but the moisturising lotion used in this study is water based with the 
second ingredient listed being glycerine. 
Eucerin® (Beiersdorf AG) is a water based moisturiser. In the survey conducted by this 
author, 12 out of 26 (46%) of the burn therapists surveyed (predominantly from US) reported 
recommending Eucerin® for scar management.5 Its ingredients include, in order of highest to 
lowest proportions, water, petrolatum, mineral oil, ceresin, lanolin alcohol, phenoxyethanol 
and piroctone olamine.60 However, the Eucerin® brand has a broad range of moisturisers so it 
is difficult to ascertain which was used by Phillips et al. (1996)61 
Aquaphor®, similar to Eucerin®, comes in a broad range of products bearing this name. 
‘Aquaphor® Healing Ointment’ contains 41% petrolatum as its main ingredient and would 
therefore be quite thick and occlusive, similar to Vaseline which is 100% petrolatum. 
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Petrolatum is commonly referred to as ‘petroleum jelly’ in Australia, and popularised under 
the brand name, Vaseline. Due to Vaseline containing only one ingredient, it can be used as a 
control moisturiser in studies examining the effects of moisturisers with more complex 
formulations or active ingredients.  
Aqueous cream has been found to increase TEWL in healthy skin and decreases the thickness 
of the stratum corneum skin.62, 63 Since scar activity may correlate with TEWL (section 
1.3.3), aqueous cream may influence TEWL in a negative direction for scar outcome. Despite 
this, aqueous cream was the second most commonly recommended moisturiser by burn 
therapists in Australia.5 The use of aqueous cream as a control moisturiser was questioned in 





1.7 The science of evidence synthesis 
Publications on the topic of evidence-based medicine began to rapidly increase in frequency 
from the mid 1990s. The term Evidence-Based Health Care (EBHC) has become the 
umbrella term to incorporate the previous terms of Evidence-Based Practice and Evidence-
Based Medicine. In the literature it appears that the terms EBP and EBM are used 
interchangeably. At its outset, the movement was very much led by Professor David Sackett 
who published extensively on the topic, although he himself reports that its philosophical 
origins extend back to mid-19th century Paris.65  
Sackett (1997)65 suggested that evidence-based medicine ‘is the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of individual 
patients. The practice of evidence-based medicine means integrating individual clinical 
expertise with the best available external clinical evidence from systematic research’.65(p3) 
This systematic review follows JBI methodology and is informed by the JBI model of EBHC. 
Joanna Briggs Institute has a pragmatic and inclusive approach in terms of evidence, and 
understands that clinicians need summaries of the best available evidence to inform their 
practice. This remains true even when high quality randomized controlled trials are not 
available. As such, JBI reviewers are encouraged to look beyond RCTs when there are none 
published and include other types of evidence in their systematic reviews, where 
appropriate.66 
The 2016 revised JBI Model shows that ‘evidence synthesis’ occurs after ‘evidence 
generation’ and includes structured outputs including systematic review, evidence summaries 
and guidelines.66  
A systematic review is ‘essentially an analysis of all of the available literature (evidence) and 
a judgement of the effectiveness or otherwise of a practice’.67(p13) The aim is to summarise the 
current state of knowledge in relation to the review question. It is termed a systematic review 
as it follows a systematic process including a series of steps which are transparent and 
reproducible for the reader. The steps are:  
 Develop a protocol.  
 State the review question.  
 Implement the inclusion and exclusion criteria for selecting the literature.  
 Detail the strategy to identify all relevant literature. 
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 Utilise critical appraisal to further refine included studies.  
 Detail how the data is extracted from the primary research.  
 Synthesise extracted data.68  
The final step including evidence synthesis ideally takes the form of a meta-analysis, which is 
a statistical technique used to combine quantitative/numerical data. Where meta-analysis is 
not possible, a narrative synthesis, which is descriptive and summarises text from multiple 
studies, is the approach used. The narrative synthesis is an approach in systematic reviews 
where instead of synthesising and manipulating numerical data with the use of statistics, the 
findings of multiple studies are summarised in a structured manner in plain text which tells 
the story of the findings from the included studies. A meta-analysis refers to the statistical 
synthesis of quantitative results from two or more studies69 and analyses whether included 
studies are significantly homogeneous or heterogeneous, i.e. how much similarity or variation 
there is between the studies. This allows for combination of data from similar studies to 
determine the overall effect of an intervention.70 A forest plot is generated to allow visual 
inspection to assess heterogeneity.70 A formal statistic calculates the probability (I2) to 






2. Methodology and method 
This chapter outlines the methods used to conduct this systematic review. The review 
question sets the scene for the review, and the inclusion and exclusion criteria are discussed 
in detail. The search strategy and how searches were conducted are clearly outlined. A 
description of how studies were selected and critically appraised is provided. Finally, how 
data is extracted and synthesised using a narrative synthesis and meta-analysis is described.  
 
2.1 Review question 
The review question is: What is the effect of moisturisers on scars?  
The objectives are to provide a summary of recommendations that are relevant to clinicians 
and consumers regarding the effectiveness of different types of moisturisers on different 
types of scars, the ideal properties of the moisturisers, and/or specific ingredients that a 
moisturiser has in order to have a positive (or negative) effect on the scar outcome. 
Presenting the moisturisers according to availability and cost can aid in decision making for 
the clinician and consumer when working together to determine the best product for the best 
outcome.  
 
2.2 Criteria for considering studies for inclusion in this review 
2.2.1 Types of studies 
The types of studies to be included was deliberately kept broad to capture the maximum 
number of studies that might address the review question. Types of studies considered for 
inclusion included experimental and epidemiological study designs such as randomised 
controlled trials, non-randomized controlled trials, quasi-experimental, before and after 
studies, prospective and retrospective cohort studies, case-control studies, case series and 
analytical cross sectional studies. Articles that were not about primary empirical research, for 
example, review articles, were not included.  
2.2.2 Types of participants 
This review considered studies including people of any age with scarring to the skin. Risk 
factors for more aggressive scarring, including dark skin, female gender, younger in age, 
increased time to healing and severity of injury,22 were considered when analysing the results 
of studies.  
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Scars from various causes were included. This included those labelled as hypertrophic, 
keloid, formed from healing by secondary intention, or a linear scar (from surgery or trauma). 
Keloid scars are defined as extending beyond the border of the original injury and are 
reported to have a different pathophysiology, genetic factors71 and a higher rate of TEWL.18 
Despite them being different from the other scars mentioned above, they were carefully 
considered to be included for this review as moisturisers are a management technique 
commonly utilised in the clinical setting. Studies examining scarring of internal structures 
(other than skin) such as connective tissue, muscle, tendon and nerves, for example, were 
excluded. 
Atrophic scars were excluded as they result from damage to the underlying structures that 
support the skin such as fat or muscle. Acne and chicken pox scars are examples of atrophic 
scars and have quite different management regimes.33 Studies conducted on animals were 
excluded. 
 
2.2.3 Types of interventions 
Moisturisers can come in many different forms. They are considered pharmaceutical products 
and can be termed cream, lotion, emollient, paste, oil, unguent or salve. These all have 
different properties but all versions can be considered to be under the broader banner of a 
‘moisturiser’. The ingredients in moisturisers can be many and varied, and when they have a 
specific active ingredient added can be considered a medicated cream. This review intended 
to include any moisturiser and therefore included all the interchangeable terms listed above, 
and medicated or un-medicated creams were also appropriate for inclusion.  
Studies that used moisturisers in addition with another conservative means of scar 
management were excluded as the effect of the moisturiser could not be determined. 
However, studies that included an active comparison of two different moisturisers were 
included, where the method of application (including rubbing it in) was consistent, for 
example, Lewis et al. (2012), where aqueous cream was compared to a beeswax and herbal 
oil cream to reduce itch.72 
 
2.2.4 Comparators  
Comparisons included a moisturiser/cream with other moisturiser/creams with or without an 
active ingredient or medication. Alternatively, the use of moisturiser was compared to no 
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treatment. As scar management includes other treatment techniques, the comparators were 
other scar treatments such as laser therapy, pressure garments or contact media, for example, 
and provided they did not compromise the findings they were included as they possibly 
reported secondary findings related to the effect of the moisturiser.  
 
2.2.5 Types of outcome measures 
This review considered studies that included outcome measures that rated changes in the scar. 
Patients reporting changes to their scars such as pain, itch, pliability and hypersensitivity are 
subjective outcome measures which may be utilised in some studies. These included 
questionnaires, visual analogue scales or part of a scar assessment scale such as the Patient 
and Observer Scar Assessment Scale (POSAS).73  
Subjective scar assessment scales such as the Vancouver Scar Scale,74 Modified Vancouver 
Scar Scale,75 and POSAS73 are only a few of the scales that were used to assess the scar’s 
physical characteristics such as colour, height, thickness/pliability and texture. They infer a 
measure of severity of the scar.  
Physical characteristics, which demonstrate the scar’s physiological activity, were measured 
by objective instrumentation such as goniometry (joint range of movement), tape measure 
(length), spectrophotometry/colorimetry (colour/vascularity), tissue tonometry (pliability),76 
standardised digital imaging and spectral modelling (vascularity and melanin),77 and 
electrical hygrometers such as the Tewameter® (TEWL).  
The occurrence or recurrence of a scar post surgical procedure combined with the use of a 
moisturiser is an outcome measure that was included. Reports on the characteristics of the 
moisturiser/cream such as patient acceptance, price paid by the patient, how well it spreads, 
fragrance, comfort and other characteristics were reported by studies. This subjective 
information would be of use to clinicians in their decision making when recommending 
moisturisers and therefore was included in this review.  
 
2.3 Review methods 
2.3.1 Search strategy 
The first stage of determining the search strategy was to clarify the PICO (Population, 
Intervention, Comparator, Outcome) question as this then allowed for expansion of the search 
terms into a logic grid. The PICO model is used to define the properties of the studies to be 
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included in the systematic review.70 The logic grid is completed by placing all the search 
terms for each component of the PICO question into a table. Each column of the table is then 
linked with an ‘and’ and the search terms within each column are linked with an ‘or’.   
The PICO question was: What is the effect of moisturiser use on scars? 
The population included any person with any hypertrophic or keloid scar. There was no need 
to limit the search to adults or children, for example, therefore no terms were required to 
further define this concept in the search and it was not included on the logic grid.  
The intervention was moisturisers. There are many different terms to describe moisturisers. 
These are shown in Table 2-1 below.  
The comparators were any other treatment, control group or no treatment. As a result there 
was no need to include any search terms in the logic grid.  
The outcomes were changes to the scar characteristics, patient reported outcomes or reports 
on the characteristics of the moisturiser. As there was no restriction to what outcomes were 
being sought there was no search terms included.  
Additional terms were found initially by examining the keywords of published articles 
already known to be close to the research question. Basic definition descriptions of the term 
‘scar’ and ‘moisturiser’ were sought from various sources, for example, Google search, 
thesaurus and research articles on moisturisers and scars. Table 2-1 provides a list of the 
initial keywords identified to guide database searching.  
 



















The databases searched were chosen with the guidance of a University of Adelaide librarian 
so as to be as inclusive as possible for the review. The databases chosen were PubMed, 
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CINAHL, Embase and Web of Science. Searches which were limited to English as there was 
no capacity to translate studies published in other languages. There were no date limits set to 
ensure maximum capture of studies. 
Each database’s thesaurus of subject headings or indexing terms was then thoroughly 
checked to customise the search terms specific to each database. With the assistance of the 
librarian, each of the search terms was refined to specify the field code (e.g. PubMed) to 
search for the term in the MeSHs (Medical Subject Heading) [mh], or as a text word [tw]. In 
the case of PubMed the choice was made to explode the search term. When the MeSHs were 
examined they demonstrated that all components under that heading were relevant to the 
topic. Where possible, wildcards (*) were used, for example, Moisturi*[tw]. This allowed for 
results to be obtained which contained US and Australian spelling of the word and different 
endings, for example:  
 moisturisers  
 moisturisers  
 moisturizing  
 moisturising  
 moisturize  
 moisturise  
 moisturized  
 moisturised.  
Appendix 1 contains the logic grids with field codes, and the search strategy for each 
database. Searches of databases were completed in September 2016 and grey literature 
searching occurred in June 2017. Once the search was completed, the results from each 
database were exported to EndNote™ software (Clarivate Analytics, USA).  
A search of the grey literature was also performed to identify any unpublished documents, 




The websites searched included:  
 https://clinicaltrials.gov/ – a registry and results database of publicly and privately 
supported clinical studies of human participants.  
 www.anzctr.org.au – Australian and New Zealand Clinical Trials Registry – an online 
registry of clinical trials being undertaken in Australia, New Zealand and elsewhere.  
 www.controlled-trials.com now called www.isrctn.com  – a primary clinical trial 
registry recognised by the World Health Organization and International Committee of 
Medical Journal Editors that accepts all clinical research studies (whether proposed, 
ongoing or completed), providing content validation and curation and the unique 
identification number necessary for publication.  
 www.opengrey.eu – the System for Information on Grey Literature in Europe is an 
open access reference on grey literature produced in Europe.  
 http://www.cochranelibrary.com/about/central-landing-page.html – the Cochrane 
Central Register of Controlled Trials. Two studies were found but both were already 
included from database searching.  
 
2.3.2 Study selection and inclusion 
Duplicate citations were removed in EndNote™. Further duplicates, not identified by the 
software, were removed manually during title and abstract screening. Screening of titles and 
abstracts occurred with consideration of the inclusion criteria (see Section 2.2). The full texts 
of studies that appeared to meet the inclusion criteria during the screening process were 
retrieved. When assessing eligibility of full-text articles, the specifics of the inclusion and 
exclusion criteria were considered to assist in decision making.  
 
2.3.3 Assessment of methodological quality – critical appraisal 
The object of critical appraisal is to ‘assess the methodological quality of a study and to 
determine the extent to which a study has addressed the possibility of bias in its design, 
conduct and analysis.’70(p59) As this systematic review utilised the JBI approach, the 




Papers selected for inclusion were assessed by two independent reviewers for methodological 
validity prior to inclusion in the review using the predefined standardized critical appraisal 
instruments available on the JBI website. Appendix 2 contains the JBI critical appraisal tools 
that were utilised for this review.  
Recruitment of a second reviewer was a similarly qualified Masters of Clinical Science 
candidate who had undergone critical appraisal and systematic review training with JBI. This 
author and the second reviewer scored the included studies independently and this author 
then compared the final scores. Any disagreements that arose between the reviewers were 
resolved through discussion. There was no need to obtain a third reviewer, however, this was 
an option had the need arisen if agreement could not be obtained.  
 
2.3.4 Data extraction 
Reported results of outcomes measured and conclusions were extracted from critically 
appraised and selected studies into a table similar in structure to that of the Included Studies 
(Table 3-1 and 3-2) and Excluded Studies (Appendix 3). Data extracted included type of scar, 
moisturiser utilised, method of the interventions, methodology of the study and results of 
outcomes measured.  
Numerical data suitable for a meta-analysis on the recurrence rates of keloids post excision 
and application of imiquimod were extracted according to location of the keloid and surgical 
technique utilised.  
 
2.3.5 Data synthesis  
The findings of the studies were grouped and outcomes were described in terms of direction 
of effects, for example, negative effect of the moisturiser on scars, no effect or a positive 
effect of the moisturiser on scars. Actual data and effect sizes, along with confidence 
intervals and the results of any statistical tests, were extracted and reported in the narrative 
synthesis where possible. 
Meta-analysis – imiquimod group 
These studies were conceptually similar in that they all looked at the outcome of recurrence 
of keloids post excision and then application of imiquimod cream. Meta-analysis was 
conducted using StatsDirect software (StatsDirect Ltd., Cambridge, UK) using the Miller 
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approach (exact inverse Freeman-Tukey double arscine) for proportional meta-analysis.78 
Following the recommendation by Munn et al. (2015)78 a random effects model was used.  
A meta-analysis was performed presenting a forest plot to illustrate the risk or proportion of 
participants that will have recurrence of their keloid following use of imiquimod. 
Heterogeneity was assessed statistically using the standard I square. Due to the wide spread 
of results in the meta-analysis of all the imiquimod studies, subgroup analyses based on the 
location of the keloids and the surgical technique was also conducted   
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3. Results of searching, selection and assessment of methodological 
quality 
This chapter outlines the results of the systematic searching and selection process. From the 
database searches, 1970 studies were retrieved and filtered down to a total of 33 studies. The 
included studies were divided into the moisturiser group and the imiquimod group which was 
a group of studies that investigated the recurrence of keloids post excision and application of 
imiquimod cream. The included studies details are presented in a table format. Critical 
appraisal of the included studies revealed interesting factors to consider when examining the 
results, presented in the next chapter.  
3.1 Results of searches 
Grey literature searching resulted in no eligible papers being identified.  
The number of records identified in the databases searched are as follows:  
 PubMed: 677 
 Embase: 1162 
 CINAHL: 72 
 Web of Science: 59 
 Total 1970 studies.  
A total of 552 duplicates were removed from the 1970 results, see Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) chart in Figure 3-1.  
3.1.1 Other searches 
Three studies were found in the reference lists of included articles.79-81 All three were studies 
on Tretinoin cream. When examining the MeSH headings for these articles, it was apparent 
that they did not appear within any of the ‘moisturiser’ search terms utilised, despite 
Tretinoin cream being a topical cream.  
A well marketed product and company in Australia, Bio-Oil® was approached to supply 
articles they self-funded.82-84 The three studies received were considered for inclusion with 
two eventually being included in the moisturiser group for narrative synthesis. Another study 
was identified by a co-worker of this author relating to a moisturiser used within Australia.72 




3.2 Screening of studies 
The following PRISMA chart illustrates the results of the searching, screening and inclusion 
process of the review. A total of 1977 records were identified through searching. Once 
duplicates were removed the title and abstract of 1425 records were screened. Seventy-two 
full text studies were retrieved and assessed for eligibility; of these 39 were subsequently 

















































Figure 3-1: PRISMA chart showing study selection, screening and inclusion process. 85  
Number of additional records 
identified through other sources 
(N=7) 
Number of records identified 
through database search 
(N=1970) 
Number of duplicate records removed  
(N= 552) 
Number of articles excluded 
on reading full-text (N= 39)  
See Appendix 3 for reasons 
Number of full-text 
articles assessed for 
eligibility (N=72) 
Number of articles included  
(N=33) 
Number of articles 




































Number of records 
excluded (N=1356) 
Number of records screened 
(N= 1425) 
Number of records 
identified by screening 





3.3 Excluded studies 
A list of the full-text studies that were excluded with reasons is provided in Appendix 3. The 
most common (15 studies) reason for exclusion when reviewing the full texts was that studies 
were only reported as abstracts. Other common causes for exclusion were that the application 
of moisturiser also involved other confounding interventions affecting the final outcomes 
(seven studies), review articles or opinion pieces (five studies) and animal studies (three 
studies). 
The primary authors were contacted for those studies that were only available in abstract 
form such as those presented at conferences.46, 86-92 Successful contact was only made with 
one author who reported their studies were conducted such a long time ago that they no 
longer had any further data to share.91, 92  
  
3.4 Included studies 
Studies were included if they met the inclusion criteria detailed in the published review 
protocol,93 also described in Section 2.2. Many studies reported on more than one outcome. 
The majority reported on scar parameters (16), followed by itch/pain (nine), cosmesis of the 
scar (eight), recurrence of keloids post excision and imiquimod application (seven), in vitro 
outcomes (four) and TEWL (one). To facilitate analysis and presentation of results, studies 
that were grouped for a meta-analysis that examined the recurrence of keloids post excision 
and application of imiquimod (imiquimod group) were reported separately from the others 
(moisturiser group). A study that appeared initially to belong to the imiquimod group was 
moved into the general moisturiser group as they did not follow the same structure (six weeks 
of imiquimod application to measure recurrence of the keloid post excision) as the other 
imiquimod studies.94 All studies were appraised and included. Details of the included studies 
are shown in Tables 3-1 (moisturiser group) and 3-2 (imiquimod group). 
 
3.4.1 Included studies: moisturiser group 
There were 26 studies in this group, including a total of 719 participants, some with multiple 
scar sites. A wide variety of products were investigated, comprising a total of 23 different 
moisturisers. Utilising the JBI Levels of Evidence,95 half of the studies (13/26)48, 56, 58, 61, 82, 83, 
94, 96-102 in the moisturiser group were RCTs (level 1c), the majority of the remainder 
(11/26)19, 31, 46, 49, 55, 57, 79-81, 103, 104 were of a quasi-experimental design (level 2c) and 2/2645, 
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105 were case series (level 4c). The majority (16/26)31, 45, 46, 48, 56, 58, 61, 79, 80, 94, 96-98, 100, 101, 104 of 
the included studies in the ‘moisturiser group’ were conducted in the Americas and Canada. 
Others were conducted in European countries (5/26)19, 49, 81, 105 and Asian countries (3/26)55, 
99, 103. Overall there was a total of 785 participants with scars included for narrative synthesis.  
Participants in the studies had a mix of differing scar types, including keloid, linear and 
hypertrophic. Some studies had mixed types of scars in the patients they examined. Figure 3-
2 below shows the number of the included studies with diverse scar types among included 
participants. The ‘1’ in the middle represents the study that utilised a scar model (tape 
stripping) to simulate all scars.19 Hypertrophic scars were the most commonly examined 




Figure 3-2: Scar types examined by studies in the moisturiser group. HTS = Hypertrophic 
scar. The ‘1’ in the middle is a scar model.  
The five studies in the hypertrophic/linear category did not specify the scar types.57, 82, 83, 94, 99 
Since they examined scars from small postoperative wounds, it was assumed that unless they 
specified otherwise the scars could be either hypertrophic or linear. Although keloid and 
hypertrophic scars are now known to be quite different scar types, they were examined 
together in the three studies.56, 61, 81 One was published in 1980,81 perhaps before it was 
established that the scars have different mechanisms for proliferation.  





3.4.2 Included studies: imiquimod group 
The imiquimod group included seven studies that examined the outcome of recurrence of a 
keloid post excision and application of imiquimod. Over the seven studies, there were 77 total 
participants with 82 total keloids. All underwent excision of a keloid which was either left to 
heal by secondary intention or was primarily closed. The length of imiquimod application 
was from six to eight weeks and the frequency of application varied from daily to three times 
a week. Utilising the JBI Level of Evidence95 the majority of the studies (5/7)30, 106-109 in the 
imiquimod group were case series (level 4c), one case report110 (level 4d) and one RCT111 
(level 1c). The imiquimod studies were mainly from the USA (3/7)30, 109, 111, with the others 
originating from South America (2/7)107, 108 and Asia/India (2/7)106, 110. Details of the studies 
are in Table 3-2 below.  
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Participants: Undergone Mohr’s 
(skin cancer removal) surgery. 
Setting: University of Miami 
Department of Dermatology & 
Cutaneous Surgery, Miami, Florida, 
USA.  
Given 2 ointments Aquaphor® labelled 
Ointment A and Ointment B which was 
Aquaphor® with contents of oral 
vitamin supplement, resulting 
concentration was 320 IU/gm, scars 
divided into parts A & B, applied twice a 
day for 4 weeks.  
Cosmetic appearance at week 1, 4 
& 12.   
Berman, 




RCT Imiquimod 5% Participants: Post surgical scars - 
removal of melanocytic nevi. 
Setting: University of Miami, 
Florida, USA. 
Subjects underwent punch elliptical or 
punch excision. Same surgeon, all 
sutured in 2 planes. Each wound 
randomised to either receive vehicle 
cream or imiquimod. Apply nightly for 4 
weeks. Also applied Bacitracin antibiotic 
cream until sutures taken out to both 
sites.   
Evaluation at 2, 4, and 8 weeks 
after surgery. Plus extra follow up 
between week 17-46 to evaluate 
long term effect of imiquimod. At 
week 8 patient and investigator 
examined the scars cosmesis, 
induration, and pigmentary 
alterations using VAS.  
Berman, 
Poochareon, 
et al. 200545 
Keloid Case series Tacrolimus 
Ointment 0.1% 
Participants: Keloids >10ys old, 
various sites, 6F:4M, 9xblack 
skin:1xwhite skin. Setting: 
University of Miami, Florida, USA. 
Open label pilot study. Applied the 
ointment 2x/day for 12 weeks without 
occlusion.  
Evaluated at baseline, 2, 7, 12 
weeks. Volume of keloid measured 
by alginate impression.  Induration 
determined by a set of rubber discs 
& recorded on VAS.  Patients rated 
pain, pruritus, erythema, tenderness, 








Design Product Participants, setting Intervention Outcomes measured 
Butzelaar et 
al. 2015105 
HTS Case series Not specified Participants: Elective cardiothoracic 
surgery through median 
sternotomy. Setting: St Antonius 
Hospital Nieuwegein and 
University Medical Centre 
Groningen, The Netherlands. 
Scars labelled normotrophic or HTS.   
 
Evaluated at 4m & 1yr. Patients 
completed a questionnaire. Also 
measured blood pressure, skin 
types, joint mobility, standardised 
photos taken. Studied risk factors: 
90 – combined into 17 categories.  





Mederma®  Participants: Recently undergone 
Mohr’s or excisional surgery for 
BCC or SCC. Setting: 
Dermatologic Surgery Unit at Beth 
Israel Deaconess Medical Centre, 
Boston, Massachusetts, USA. 
Split scar study. Treatment – onion 
extract gel (Mederma®). 
Control – petrolatum ointment.    
Provided treatments in opaque syringe & 
labelled.  
Applied 3x/day for 8 weeks.  
Evaluated at 2, 8 & 12 weeks from 
start of treatment & 11months via 
phone. Physician evaluation – 
assessors blinded. VAS for redness, 
thickness, overall cosmetic 
appearance.  
Patient evaluation – used VAS rate 
redness, itching, burning and pain. 
And phone interview to rate 

















Participants: >2yrs post whole 
facial burn scars. Setting: Tertiary, 
Institutional, Sao Paulo, Brasil. 
Patients applied 5 drops of Tretinoin 
every night on their face without 
massaging and washed their face in the 
morning.  
Skin biopsies were obtained 
initially and after one year of 
treatment. The resistance and 
elastance of 
these skin biopsies were measured 
using a mechanical oscillation 
analysis system. The density of 
collagen fibres, 









Doxepin Participants: Minor burns who 
complained of itch, not 
>15%TBSA. Healed wounds. Scars 
6weeks - 3months. Setting: 
outpatient clinic, Brigham and 
Women's Hospital Burn Centre, 
Boston, Massachusetts, USA. 
Standard care group: oral antihistamine, 
skin moisturiser 3x/day of the patient’s 
choice as long as it did not have 
antihistamine properties. Doxepin group: 
applied cream in a thin layer to the itchy 
area 4x/day (every 6 hrs), then 20min 
later moisturiser of choice.  
Treatment modality in each group 
continued for 3 months or until itch 
stopped and no longer required 
treatment. 
 
Measurement of itch & erythema by 
research team. Initial and 
subsequent done by them.  
Itch – VAS, patients recorded daily 
minimum & maximum itch score 
for the day, averaged by the 
researchers and antihistamine 
adjusted in the standard care group. 
Pain – VAS, Erythema – VSS, 
digital photography. Participants sat 









Design Product Participants, setting Intervention Outcomes measured 







Participants: Specimens collected 
from active keloids of patients. 
Setting: Xuzhou Central Hospital 
and Xuzhou Hospital of Traditional 
Chinese Medicine, Jiangsu, China.  
Drug preparation: 1g/ml – high 
concentration group, 0.5g/ml medium 
concentration group, 0.25g/ml for low 
concentration group, and a control 
group.  
Fibroblasts of keloids cultured in 
medium. Fibroblasts then mixed with the 
drug. 
Cell proliferation rates measured as 
a % of the control (no drug). DNA 
cycles of keloid fibroblasts also 
recorded at different concentrations 







Putrescine Participants: Patients with one or 
more unrevised HTSs. Setting: 
University of Manitoba, Canada.  
Putrescine compounded in eutectic base 
at 0.8% concentration (Fibrostat). 
Identical in odour and appearance to the 
sham treatment which was the ointment 
base alone. Patients applied the ointment 
daily and occluded with Duoderm CGF 
or Actiderm. After 1 month the patient 
received the other topical preparation for 
an additional month.   
Measurements taken at baseline, 1m 
& 2m. Scars rated on a rating scale. 
Photographic analyses at 1 month 

















Alhydran Participants: Tape stripped skin on 
healthy normal subjects. Setting: 
Ghent University Hospital, Ghent, 
Belgium 
3 silicone gels (liquid) and hydrating gel 
cream (Alhydran®, BAP Medical, 
Belgium).  
2 Test areas, one on each forearm, then 
divided into 4 subareas.  
One control area – normal skin 
One stripped area = scar like control.  
Stripped subareas for application of each 
of the 4 products.  
Process: 30min of acclimatisation. 
Baseline measures of TEWL & 
hydration on every subarea. Then 
stripping of all the areas except the 
control site. 5min after stripping TEWL 
measured to identify increased TEWL. 
Application of the 4 products. TEWL 
measured every hour and hydration at 
the end after 3 hours.  

















Participants: Scars from Mohr's 
surgery. Setting: University of 
Texas, Houston, USA 
Assigned to one of 2 treatment groups 
on a rotating basis. Group 1 – 
Mederma® 3x/day for 1 month. Group 2 
– Aquaphor® 3x/day for 1 month. 
VAS on erythema and itching and 
photos at onset and completion.  





Imiquimod 5% Participants: Excised keloid scars. 
Setting: University of Miami, 
Miami, USA.  
Keloids were present 6 months to 3 
years and were untreated for at least 2 
months. Control: no imiquimod 
treatment. For the treated tissue, 
imiquimod 5% cream had been applied 
to the skin once daily by the subject for a 
minimum of 2 weeks and a maximum of 
2 months. Tissue was only included if 
the keloid had been excised within 48 h 
of cessation of imiquimod therapy. Each 
keloid had a confirmed haematoxylin 
and eosin diagnosis by a 
dermatopathologist. Total RNA 
extracted, cDNA probes synthesized.  
Expression levels of genes 



















Participants: Scars from multiple 
causes (burns, trauma, post 
surgery). Setting: Red Cross 
Hospital, The Hague, The 
Netherlands.  
Retinoic acid (005%) as a topical 
application apply the solution to their 
scars twice a day. Several patients had 
received Kenacort intralesionally prior 
to treatment with retinoic acid. Excluded 
if treatment was shorter than 3months.  
Three months after completion of 
this study all patients received a 
questionnaire requesting them to 
answer twelve questions about their 
subjective findings of the 
effectiveness of the drug. These 
questions included improvement or 
disappearance of pain and/or itching 
as the main parameters. 
Jenkins et al. 
198698 




Participants: Grafting for post burn 
contractures of the neck and axilla 
and interdigital webs of the hand. 
Setting: Shriners Burns Institute, 
Cincinnati, USA.  
Allocated to groups: Base cream 
(Aquatain), Aristocort® A (Aristocort® 
0.1% in Aquatain) or base cream with 
Vitamin E, 200 units/gm. Used the study 
cream on discharge and continue for 120 
days. Massaged in 3x/day for 3min.  
ROM, scar thickness not he edge of 
the graft, cosmetic appearance. 
Photographs pre op and at each 
follow up. Graded for scarring & 
cosmetic appearance by 
independent blinded observers. 
Patients with neck and axillary 
grafts evaluated for contracture by a 
pliable impression cast of the 
grafted area 1m, 4m, 1yr post-op. 







KeragelT® Participants: Adults having an 
operation involving median 
sternotomy. Setting: Cardiothoracic 
Surgery Department, Christchurch 
Hospital, New Zealand.  
At 7 days post op, each half of the 
patients scar was randomised to receive 
keratin gel (KeragelT®) or Aqueous 
Cream. Patients self-administered both 
products for twice a day 6 months.  
Patients reviewed at 3 and 6 
months. Assessed using Manchester 
Scar score and POSAS (both 
observer and patient rated 








Design Product Participants, setting Intervention Outcomes measured 








Participants: Patients with 
postoperative wounds. Setting: 
Wonkwang University School of 
Medicine, Iksan, Korea.  
Patients randomly allocated to groups. 3 
groups - Silicone gel (Dermatix), or 
Tretinoin cream applied both applied 
twice daily for 6months or no treatment. 
Gel, cream or nothing applied to the 
wound the day after removal of the 
stitches. 
mVSS at 0, 4, 8, 12 & 24 weeks to 







Bio-Oil® Participants: burns and surgical 
scars, new - 3yrs old. Setting: 
Photobiology Laboratory of the 
Medical University of South Africa.  
Subjects had matching scars or a scar 
large enough to allow a half-half scar 
application and intra-subject 
comparison. Product applied twice daily 
for 12 weeks to the targeted area. 
 Assessments conducted at 0, 4, 8 
and 12 weeks. Change in 
appearance judged according to: 
- Vascularity (redness) 
- Pigmentation (difference in colour 
from surrounding skin) 
- Thickness (width) 
- Relief (height) 















Eye Cream  
Participants: Patients who 
underwent bilateral upper eyelid 
blepharoplasty. Setting: Bascom 
Palmer Eye Institute, University of 
Miami Miller School of Medicine, 
Miami, USA. 
Week 2 post-op each subject was 
randomized to receive treatment of 
Lumière Bio-Restorative Eye Cream on 
one upper eyelid and no treatment on the 
other upper eyelid. Application of the 
study product in the morning and at least 
30 minutes prior to bed. Applied the 
product twice a day for 12 weeks total.  
Subjects completed a diary to assess 
effects of product on a 4-point scale 
including pain, itching, redness, and 
peeling. Subjects returned at weeks 
6, 10, and 14. Standardized 
photographs taken, principal 
investigator completed a live 
assessment to evaluate: scar 
appearance, overall appearance of 
eyelid skin, and comparison 
between eyelids. Subject completed 
a self-assessment with a 4-point 
scale to evaluate pain/soreness, 
tenderness, itching, swelling, 
redness, and eye irritation for both 
the treated and non-treated eyelid. 
Subjects also evaluated the 
appearance of the scar and overall 
eyelid. At the study exit subjects 
rated whether they would 








Design Product Participants, setting Intervention Outcomes measured 






Provase®® Participants: Patients who were 
experiencing itch as the result of a 
burn injury. Setting: Villa Medica 
Rehabilitation Hospital, Montreal, 
Canada 
Participants randomly assigned to either 
control moisturiser or protease-
containing moisturiser (Provase®). The 
moisturiser base used for both was 
identical. The investigators and 
participants were blinded to the 
treatment groups. Each participant was 
instructed to apply the moisturiser 
evenly to the pruritic area at least every 
8 hours. Before applying the moisturiser, 
participants recorded current itch or pain 
at the treatment site using a VAS which 
- no itch (pain) and the worst itch (pain) 
imaginable. Thirty minutes later, 
participants again recorded their current 
itch or pain using the VAS. 
The participant’s demographics, 
history, burn and itch TBSA, burn 
and itch locations, skin and scar 
condition, baseline scoring of itch, 
and baseline scoring of general and 
localized pain severity were 
evaluated and recorded during the 
screening and on a weekly basis for 
4 consecutive weeks. Measures – 
questionnaire on pruritus, mVSS, 










Participants: Patients with 
hypertrophic burn scars. Setting: 
hospitalised patients, Nippon 
Medical School Hospital, Tokyo, 
Japan. 
Applied mugwort lotion to 15 sites and 
control heparinoid ointments, two 
different regions of severe itchiness were 
selected in each patient. The lotion was 
applied twice daily (in the afternoon and 
before bedtime) to the selected itchy 
regions.  
Questionnaire on itch severity 
administered at 1 week and 2 










Participants: Keloid patients, 
present for average 7 yrs, 
paediatric. Setting: Faculty of 
Medicine, University of San Luis 
Potosi, Mexico.  
Cream applied twice a day for 12 weeks.  Evaluation using photos, tape 
measurements and volume using 
dental moulages. Taken prior to 








Design Product Participants, setting Intervention Outcomes measured 







Participants: adult subjects with 
keloid or HTS 0.5-2.5cm diameter. 
Setting: recruitment via 
advertisements in hospitals and 
clinics within University of Miami 
Miller School of Medicine and 
external advertisements in the 
Miami-Dade Metrorail, USA.  
Random assignment (computer 
generated randomization list) to receive 
one of 3 creams, use for 16 weeks. 
Mederma®, Scarguard®/HSE (0.5% 
hydrocortisone, silicone and VitE) and 
Cetaphil® (placebo/control). Applied 
HSE twice daily,  
Applied OE 3-4x daily.  
Applied placebo 2x daily, i.e. as per 
package instructions.  
 
Evaluate at baseline, 4, 8, 12 & 16 
weeks. Adverse events, photos, scar 
volume using alginate impression. 
Subjects and investigator assessed 
scar parameters – volume, length, 
width, height, induration, erythema, 
pigmentation, pain, itch, tenderness, 
cosmetic appearance with VAS. 
Subjects also assessed satisfaction 
with treatment with a VAS.  




RCT Eucerin® Participants: Patients with HTS 
scar, 1 patient in each group had 
keloid scar, the rest were HTS's. 
Setting: Department of 
Dermatology, Boston University 
School of Medicine, Boston, USA.   
Patients allocated to either hydrocolloid 
dressing group or moisturiser group. 
Scar cleaned with saline. HCD applied 
dressing and left for up to 7days or was 
replaced if it became dislodged. 
Moisturiser applied once daily.  
Measurements day 0, 14, 28, 56 and 
subsequently 1 month after the last 
dressing change. Evaluations by 
blind assessor. Scar volume 
measured with alginate.  
Photographs.  
Transcutaneous oxygen measures of 
the skin adjacent and the scar.  
Parameters – size, pigmentation, 
vascularity, pliability, pain, itch, 
height, VSS, patient symptoms 








Design Product Participants, setting Intervention Outcomes measured 
Prado et al. 
2005101 
Linear RCT Imiquimod 5% Participants: post breast 
reconstruction surgery. Setting: 
Department of Plastic Surgery 
School of Medicine, Jose Joaquin 
Aguirre Clinical Hospital, 
University of Chile, Santiago, 
Chile.  
First group of 5: R breast scar control - 
no treatment. Left breast - imiquimod 
beginning 2m after surgery. Gently 
rubbed cream on for 3-4 days once every 
3-4 days for 8 weeks. Second group of 5: 
imiquimod on R same as others and L 
with petrolatum application. Third group 
of 5: double blind application.  
Scar assessed with Strasser 
(cosmesis) and Beausang (scar 







Bio-Oil® Participants: scars newly formed - 
3yrs old, different locations. 
Setting: proDERM Institute for 
Applied Dermatological Research, 
Hamburg, Germany 
Subjects had matching scars or a scar 
large enough to allow a half-half scar 
application and intra-subject 
comparison. 
- Product applied twice daily for 8 
weeks, no additional massaging 
performed on the target area. 
- Application performed under 
supervision at regular intervals. 
Assessments conducted at 0, 2, 4 
and 8 weeks. Different scar 









Design Product Participants, setting Intervention Outcomes measured 









Participants: Patients 4-8 weeks 
after cardiothoracic surgery 
involving sternotomy. Control 
group of patients before surgery 
with healthy skin. Another group of 
patients 1yr post surgery to provide 
a sample of mature scar tissue. 
Setting: St Mary's Hospital, 
London, UK. 
3x3cm area at lower scar marked out. 
One group had a single application of 
Dermovate then covered with Tegaderm 
& returned 48hrs later for sample 
provision.  
Another group of patients applied the 
cream in marked areas of the scar 2x/day 
for 7 days.  
 
Photo taken using standard method. 
Two samples of scar tissue were 
obtained from each patient. First 
was from within the marked area 
(where the steroid based cream had 
been applied) and the second 
sample was from an adjacent area 
of the scar where cream had not 
been applied. 2 observers 
independently ranked the 
photographs and the biopsy slides 
from each patient. Photos assessed 
for width of scar and if it was 
flattened/raised. Biopsy specimens 
were compared. Score assigned as 
to whether steroid resulted in an 
increase or decrease of PCP1. 
Correlation coefficient was used to 
test the correlation between the 
degree of PCP 1 staining and the 
severity of the scar.  
RCT = randomised controlled trial, HTS = Hypertrophic scar, VAS = visual analogue scale, TEWL = trans-epidermal water loss, ROM = range of motion, mVSS = modified 




Table 3-14: Included studies - imiquimod group  
Study Keloid 
location 
Design Participants, setting Intervention Outcomes measured 
Berman & 
Kaufman 200230 
Earlobe, back  Case 
series 
Participants: Keloids present for 
>1yr, free from Rx for 2m, >18yo.  
Setting: University of Miami, 
Department of Dermatology and 
Cutaneous Surgery, Miami, USA.  
Keloids excised with primary bilayer 
closure. Applied imiquimod nightly 
beginning post op for 8 weeks. 
Assessed at 4, 8, 16 & 24 weeks for 
erythema, pain, pruritus, erosion, 
hyperpigmentation.  








Participants: Keloids >1yo and stable 
in size over last 6m, patients >12yo. 
Setting: University of Miami, 
Department of Dermatology and 
Cutaneous Surgery, Miami, USA.  
Tangentially shaved keloids between 
0.25cm and 2cm. Treatment group - 
imiquimod nightly. Control group - vehicle 
cream nightly. Both nightly for 2 weeks 
post-op then 3 nights a week under a semi-
occlusive non-silicone dressing for 4 more 
weeks.   
 Tolerance assessed by patient self-
assessment on VAS (0=best, 10=worst) 
of pain, tenderness and pruritus at 
week 2, 6 and 6m. 





Participants: Stable keloids. >18yo. 
Duration of keloids 1.5-30yrs. Size 
ranged from 90-882mmsq.  Setting: 
General Hospital of Sao Paulo 
University Medical School, Sao 
Paulo, Brazil.  
Keloids excised and wounds sutured with 
bilayer closure. Applied imiquimod for 8 
weeks nightly. 
Evaluated at week 2, 4, 8, 12 & 20 
weeks post op. Occurrence of 
erythema, pain, erosion, systemic 
symptoms. Pictures taken before 









Participants: Keloids >1yr old, no 
treatment for 2m, patients >18yo. 
Setting: Faculty of Medicine, Siriraj 
Hospital, Mahidol University, 
Bangkok, Thailand.  
Keloids primarily excised, sutured in two 
layers. Applied imiquimod on alternate 
nights for 8 weeks starting from 1 week 
post stitch removal.   
Assessments at week 4, 6, 8, 16, 24. 
Assessment of erythema, pain, 
pruritus, erosion and 





Participants: Keloids with no 
treatment for last 3m. Age 15-29. 
Size 0.15-10.5cmsq, mean 3.86cmsq. 
Setting: Dermatologic surgery clinic 
at University of Puerto Rico Medical 
Sciences Campus, San Juan, Puerto 
Rico.  
Keloid parallel shave removal. Then apply 
thin film of imiquimod without occlusion 
nightly, wash off in morning, for 8 weeks 
then just soap & water for remaining 16 
weeks.  
Evaluation at 2, 4, 6, 8 for adverse 
events, then monthly until completion. 
If both earlobes - compared to 
intralesional steroid inj.  
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Participants: 2 patients, keloids free 
from any treatment over the last 3m. 
Setting: Department of Dermatology 
and Venereology, All India Institute 
of Medical Sciences, New Delhi , 
India 
Keloids excised with radiofrequency under 
local anaesthetic. Imiquimod applied 
immediately, daily, for 8 weeks. Left to 
heal by secondary intention. 
Examination every 2 weeks for 12 
weeks to check for recurrence.  
Stashower 2006109 Earlobes Case 
series 
Participants: Keloids with no 
treatment for last 6m. Duration 4-
10yrs, size 1.2-2.9cmsq. Setting: The 
Clinical Centre of Northern Virginia, 
Fairfax, USA. 
Tangential excision to non-keloidal tissue 
but some could not be completely excised. 
No sutures, allowed to heal by secondary 
intention. Post-op imiquimod applied for 6 
weeks with dressing if not healed.  
Follow-up every 3-8 weeks for 12 
months - patients report on itch, pain & 
discomfort.  




3.5 Critical appraisal 
All of the 26 studies in the moisturiser group and seven in the imiquimod group were 
critically appraised using the process detailed in Section 2.3.3. The critical appraisal tools 
utilised are shown in Appendix 2 and outline the questions asked.  
 
3.5.1 Methodological quality of included studies – moisturiser group 
Although the majority are RCTs the average total score of each study was 66% (Table 3-3). 
The included RCTs generally performed well with blinding of the outcome assessors 
(question 6) and measuring the outcomes the same way for the treatment groups (question 
10).  
Bio-Oil® studies were sourced by this author direct from the company for this systematic 
review since it is a product that has been extensively marketed in Australia, and is one that 
patients frequently ask about. The company provided reports of three unpublished studies. It 
is known that at least one study was funded by the owner and developer of Bio-Oil®, who 
engaged a private laboratory to run the trial. This study was excluded from further review 
when the brand owner and developer declined a request to provide more details. The other 
two studies82, 83 were of a similar nature, from a private laboratory and only available from 
the company, and were likely also to be funded by Bio-Oil®’s owner. Apart from the 
concerns regarding the funding source of these studies, upon critical appraisal they scored 
lowest and third lowest among the included studies. The studies reported improvements in 
scar parameters reported as a percentage of improvement but statistical significance was not 
provided.  
In the RCT by Dolynchuk et al. (1996)48 they compounded Putrescine in a eutectic base at 
0.8% w/v concentration to make Fibrostat. The reported results indicated that the Fibrostat 
resulted in significantly better scar rating scores in comparison to the base cream as a 
control.48 However, there were a number of issues with the methodology. The description of 
the scars was only that they were hypertrophic, with no indication of age of scar. There was 
also no detail provided on whether the treatment groups were similar at baseline, although the 
cross over design may have eliminated this issue. The outcome measure was a scar rating 
scale that has not been published although the authors reported that the scale had a high 
kappa coefficient for inter-observer reliability.48 
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Jenkins et al. (1986)98 was not clear on whether the treatment groups all received the same 
treatment as the author referred to the fact that some applied ‘braces’ but it was not specified 
which subjects had and which had not. It is likely that these would have had an effect on the 
scar parameters being measured. 
Critical appraisal of the Baumann et al. (1999)96 study resulted in low scores due to lack of 
detail in the description of the study but also because clinically it would have been difficult to 
make comparisons as they did not specify the duration post-surgery of each patient at the start 
of the study. 
In the study examining Lumiere Bio-Restorative Eye Cream with linear scars, the comparison 
was an ‘untreated side’ and therefore received no moisturiser at all.100 However, an outcome 
measure, that is, whether they would recommend the product, was flawed, as the participant 
had no comparison.  
The study by Perez et al. (2010)56 had some methodological issues as the subjects had 
different scar types (keloid or hypertrophic scar), different skin types and were in variable 
locations. There was no record of the age of the scars, and whether they were active or 
mature scars. In addition, there were small numbers (five) in each of the three groups. 
Nedelec et al. (2012) examined whether Provase® would reduce post burn itching relative to 
the base moisturiser in Provase®.58 They were able to demonstrate that itch was reduced in 
duration, weekly frequency, number of itch episodes per day, itch total body surface area 
(TBSA), and the reported affective burden of itch.58 However, there were only nine subjects 
in each group. The author reported that the study was likely statistically underpowered.58 
They also acknowledged that larger studies were required to determine the effect of 
prolonged use of Provase® as this study was only over four weeks and that stratifying the 
subjects according to time post burn was required to examine the effects on acute and chronic 
scars.58  
Phillips et al. (1996)61 reported on Eucerin® and was based in the US. However, this study 
had some methodological issues and did not score well in the critical appraisal process (8/13, 
62%) as details of how the RCT was conducted were unclear. Of note, there was a reported 
mix of hypertrophic and keloid scars with no clear reporting of the outcomes of each of the 
types of scars. The progression of the scars within the moisturiser group which applied 
Eucerin® may have been due to natural scar progression but without details of the types of 
scars or the age of the scar this was difficult to determine. 
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It was difficult to determine the outcome of the petrolatum in the study by Prado et al. 
(2005)101 as there were two control groups, one with petrolatum and one with no treatment, 
and the data from both of these ‘control’ groups was combined to compare against the scores 
of the imiquimod group. 
The quasi experimental set of studies performed better in critical appraisal with an average 
total score for each study of 78% (Table 3-4). These studies generally performed well in 
question 1 by clarifying what was the cause (e.g. scar) and the effect (e.g. cosmesis, scar 
erythema, itch, etc.), and in question 7 by measuring the outcomes of participants in the same 
way. The Jacob et al. (2003)31 and Ding et al. (2015)103 studies received a ‘N/A’ score for 
question 6, which asked if follow-up was complete as the studies examined gene markers and 
cell proliferation post-intervention in vitro and therefore there was no follow-up as such. The 
lowest scoring study was the oldest study to be retrieved, dated 1980.81 The data was so poor 
that in a section of the study the percentages did not appear to add up. The study was still 
included to ensure the full breadth of data collated on the topic.  
There are concerns with the methodology of the Demling et al. (2003)46 study. There was no 
control group using a non-medicated cream. The patients were selected as being at six weeks 
to three months post-burn when itching is at its worst. However, this period is also the period 
of highest scar activity so the participants will have a high level of erythema. As the study 
extended over three months, this is an adequate time frame for scars to naturally begin to 
reduce in their activity and for a reduction in erythema and itch intensity as well.  
In Riaz et al. (1994),49 some details in the publication were not entirely clear, such as the 
incidence of any adverse events, whether patients had or had not applied any other treatments 
to their scars during the course of the study and the demographics of all participants. 
The Dematte et al. (2011)79 study of Tretinoin (Retinoic Acid/Vitamin A) had a significant 
positive effect on cosmesis as it improved the overall pliability of extensive full facial scars. 
The study scored well in critical appraisal as it appeared to have a robust methodology. In 
addition, clinically it was most relevant as it utilised subjects with full facial scars, who 
represent the most challenging and severe cases treated by burn therapists.  
Jina et al. (2015)57 conducted a study over six months to determine the effects with a keratin 
gel product, KeragelT®, on median sternotomy scars by comparing it to aqueous cream. 
Critical appraisal of this study resulted in a score of 100%. However, the use of aqueous 
cream as a control moisturiser may not have been a wise choice since aqueous cream has 
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been shown to increase TEWL62 and therefore may impact negatively on the developing scar. 
The study examined scar scale scores post median sternotomy, which is at a higher risk of 
hypertrophic scarring. There was no mention of whether the nine subjects provided enough 
statistical power. 
Ogawa et al. (2008)55 did not perform as well in critical appraisal as it lacked details on 
methodology. The control lotion was not described, making it difficult to assess the 
comparison of the two groups. 
Two studies were classified as case series (Table 3-5). They performed relatively well but 
both were unclear on whether they had consecutive and complete inclusion of participants 
(questions 4 and 5). Berman et al. (2005)45 did not report outcomes clearly (question 8) on 
tacrolimus ointment, and an important observation that was not highlighted by the critical 
appraisal tools was that the study was funded by the manufacturer of the moisturiser, 
Fujisawa Healthcare Inc. Similarly, it was noted that the Berman et al. (2005)94 RCT primary 
author was a consultant for 3M Pharmaceuticals, which manufactures imiquimod.  

















Refer to Appendix 2 for details of questions. Y=Yes, N=No, U=Unclear 
 
  
Question 1 2 3 4 5 6 7 8 9 10 11 12 13 Score % 
Study                
Baumann 199996 N U U Y Y Y Y Y Y Y U N U 7/13 54 
Chung 200697 U U Y Y Y Y Y Y Y Y Y Y Y 11/13 85 
Dolynchuk 199648 U U U Y Y Y Y Y Y Y Y Y Y 10/13 77 
Jenkins 198698 Y N Y Y Y Y U Y Y Y Y U Y 10/13 77 
Kwon 201499 U U Y U U U Y N Y Y Y Y N 6/13 46 
Murdock 2016100 U U Y N N Y Y Y Y Y Y Y Y 9/13 69 
Nedelec 201258 Y Y N Y Y Y Y U Y Y Y Y Y 11/13 85 
Perez 201056 Y Y Y Y Y Y U U Y Y Y Y Y 11/13 85 
Phillips  199661 U U N N N Y Y Y Y Y Y Y Y 8/13 62 
Berman, Frankel 
200594 
U U Y Y Y Y Y Y Y Y Y Y Y 11/13 85 
Prado 2005101 Y Y Y Y Y Y Y Y Y Y Y Y U 12/13 92 
Medunsa 200582 U U U N U Y Y U U U U U U 2/13 15 
proDERM 201083 U U U U U Y Y U U Y Y N U 4/13 31 
Scores 4/13 3/13 7/13 8/13 8/13 12/13 11/13 8/13 11/13 12/13 11/13 9/13 8/13  Ave 66% 
%'s 31 23 54 62 62 92 85 62 85 92 85 69 62   
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Table 3-4: Critical appraisal scores for Quasi Experimental studies in moisturiser group  
Questions 1 2 3 4 5 6 7 8 9 Score % 
Study            
Demling 200346 Y Y Y Y Y U Y Y U 7/9 78 
Hoeksema 201319 Y Y Y Y Y Y Y Y Y 9/9 100 
Jacob 200331 Y U Y Y Y NA Y Y U 6/8 75 
Jina 201557 Y Y Y Y Y Y Y Y Y 9/9 100 
Riaz 199449 Y N Y Y Y U Y Y Y 7/9 78 
Dematte 201179 Y Y Y Y Y Y Y Y Y 9/9 100 
Janssen de Limpens 198081 Y U U N N N Y N N 2/9 22 
Panabiere-Castaings 198880 Y U U N Y Y Y U Y 5/9 56 
Ding 2015103 Y Y Y Y Y NA Y Y Y 8/8 100 
Jackson 1999104 Y U U Y Y Y Y Y Y 7/9 78 
Ogawa 200855 Y U U Y N Y Y Y Y 6/9 67 
Scores 11/11 5/11 7/11 9/11 9/11 6/9 11/11 9/11 8/11  Ave 78% 
% 100 45 64 82 82 67 100 82 73   
Refer to Appendix 2 for details of questions. Y=Yes, N=No, U=Unclear, N/A=Not applicable 
Table 3-5: Critical appraisal scores for Case Series in moisturiser group.  
Questions 1 2 3 4 5 6 7 8 9 10 Score % 
Study             
Berman, Poochareon 
200545 
Y Y Y U U Y Y N Y U 6/10 60 
Butzelaar 2015105 Y Y Y U U Y Y Y Y Y 8/10 80 




3.5.2 Methodological quality of included studies – imiquimod group 
The group of studies that measured the outcome of recurrence of keloids post excision and 
imiquimod application contained one RCT (Table 3-6).111 It did not perform well in the 
critical appraisal, scoring only 54% of ‘Yes’ for the questions. The follow-up was not 
complete (question 8) and did not use appropriate statistical analysis (question 12). In 
addition, many components were unclear such as concealment of allocation to treatment 
groups (question 2), similarity of treatment groups at baseline (question 3), and blinding of 
participants (question 4) and those delivering treatment (question 5).  
The case series in general performed satisfactorily for inclusion in this review with an 
average score of 82% (Table 3-7). They regularly performed well in reporting of the 
outcomes (question 6), definition of the condition (question 7), and reporting on the 
demographic (question 4) and clinical information (question 5) of the participants. Only one 
study fulfilled all of the appraisal criteria.108  
The one case report by Malhotra et al. (2007)110 study was considered a case report as even 
though there were two patients, they were reported as two separate cases (Table 3-8). It failed 
to get a ‘Yes’ for all questions as it did not clearly describe the patients’ history (question 2), 
assessment methods were not clearly described (question 4) and it was unclear if there were 
adverse events (question 7).  





Table 3-6: Critical appraisal scores for randomised controlled trial in imiquimod group. Refer to Appendix 2 for details of questions. Y=Yes, 
N=No, U=Unclear. 
Questions 1 2 3 4 5 6 7 8 9 10 11 12 13 Score % 
Study                
Berman, Harrison 2009 
111 
Y U U U U Y Y N Y Y Y N Y 7/13 54 
Refer to Appendix 2 for details of questions. Y=Yes, N=No, U=Unclear 
 
Table 3-7: Critical appraisal scores for case series studies in imiquimod group 
Questions 1 2 3 4 5 6 7 8 9 Score % 
Study            
Berman, Kaufman 200230 Y Y U Y Y Y Y Y Y 8/9 89 
Cacao 2009112 N Y U Y Y Y Y Y Y 7/9 78 
Chuangsuwanich 2007106 Y Y Y Y Y Y Y N N 7/9 78 
Martin-Garcia 2005 108 Y Y Y Y Y Y Y Y Y 9/9 100 
Stashower 2006 109 U U U Y Y Y Y Y N/A 5/8 63 
Scores 3/5 4/5 2/5 5/5 5/5 5/5 5/5 4/5 3/4  Ave 82% 
%'s 60 80 40 100 100 100 100 80 75   
Refer to Appendix 2 for details of questions. Y=Yes, N=No, U=Unclear, N/A=Not applicable 
 
Table 3-8: Critical appraisal scores for case report in imiquimod group 
Questions 1 2 3 4 5 6 7 8 Score % 
Study           
Malhotra 2007 110 Y N Y N Y Y U Y 5/8 63 
Refer to Appendix 2 for details of questions. Y=Yes, N=No, U=Unclear 
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4. Review findings 
This chapter describes the included studies by drawing out their findings on the effect of 
moisturisers on scar outcomes. The outcomes of cosmesis, scar parameters, itch/pain, TEWL, 
and in vitro findings are described utilising a narrative synthesis. The outcome of recurrence, 
particularly of keloids post excision and application of Imiquimod cream, is described using a 
meta-analysis. Amongst the results we also highlight the adverse events reported for many 
products.  
Narrative synthesis of the effect of moisturisers on scars 
When examining all 26 studies it became apparent that studies could be grouped according to 
the outcomes they reported on. This included cosmesis, scar parameters, itch and pain, trans-
epidermal water loss, and in vitro outcomes.  
4.1 Cosmesis of the scar 
There were a number of studies that specifically reported on cosmesis of the scar (Table 4.1). 
Murdock et al. (2016)100 studied the effects of Lumiere Bio-Restorative Eye Cream after 
upper eyelid blepharoplasty in a split face randomised study. Patients were asked to choose 
which eyelid had a better appearance. The number of patients who selected the treated side as 
better than the control side increased from 50% (10/20) to 70% (14/20) from week 2 to week 
10, which was a statistically significant improvement (p=0.001). The investigator rated 
assessment observed 60% (12/20) of treated side eyelids to be better than the control side at 
week 10.100 The treated side achieved its final appearance earlier which ended up being the 
same as the control/untreated side by the end of the study at week 14 (p=1.00).100  
There was little to no cosmetic benefit found when using tacrolimus ointment in five out of 
six subjects with keloids.45 Patients rated the improvement in the keloid on a five-point scale. 
Overall improvement was rated as 4 – ‘poor’. Only one patient rated the improvement as 3 –
‘satisfactory’.45   
Baumann et al. (1999)96 found that cosmesis was no better with the use of vitamin E added to 
Aquaphor® (a basic moisturiser) and, in a few patients, the outcome was superior to the 
control side (Aquaphor® only). After 12 weeks of use, the physician assessment was that 
10% (1/10) of scars were assessed as having a better cosmetic outcome from use of the 
vitamin E cream, 30% (3/10) of control scars were better than vitamin E and 60% (6/10) 
showed no difference between use of the control cream and the vitamin E cream.96 When the 
patients assessed their scar for cosmetic outcome at 12 weeks, 30% (3/10) felt the control was 
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better and the remaining 70% (7/10) felt there was no difference.96 Jenkins et al. (1986)98 also 
failed to find a significant difference (reported as ‘not significant’, no p value given) in the 
cosmetic outcome of vitamin E cream when compared to its base cream and Aristocort® 
cream (a topical steroid). The data on the cosmetic outcome after one year for axillary and 
neck grafts with the use of each cream was spread evenly across the ratings of excellent, 
good, fair and poor for all three creams. 
Dematte et al. (2011) reported that skin distensibility, measured as a decrease in resistance 
31.4% (p=0.003) and elastance 14.8% (p=0.047), improved with prolonged use of Tretinoin 
cream and this would impact upon cosmesis.79  
Onion extract gel (Mederma®) was found to have no significant effect on cosmetic 
appearance when compared to petrolatum at all time points of a study.97 At 12 weeks 86% 
(12/14) were rated as having no difference between Mederma® and petrolatum, and one 
subject from each group had an overall cosmetic appearance that was better (T-test p=0.9806, 
Wilcoxon test p= 0.9583). Perez et al. (2010)56 also reported only a ~25% improvement 
(taken from graph – Figure 1 in the publication) in keloid and hypertrophic scars (p value not 
reported, but reported as not statistically significant) cosmetic outcome with Mederma® 
cream at 16 weeks compared to baseline. However, they did find improvements in 
investigator rated cosmesis for the Scarguard®/HSE moisturiser (~67%, p=<0.01) subject 
rated cosmesis Scarguard®/HSE (~48% improvement, p<0.01) and the ‘placebo’ – 
Cetaphil® (~58% improvement, p=0.01).  
When the cosmetic outcome of imiquimod cream was assessed (VAS, 0=best, 10= worst) 
with its use on linear or hypertrophic scars, it was found that in comparison to just its vehicle 
cream as the placebo, the results were often worse and occasionally the same.94 At week 8 the 
mean scores for the patient cosmetic assessment was 3.2 and 2.7 (p=0.140) for the imiquimod 
cream and placebo, respectively.94 Investigator assessment of cosmesis was 4.4 for the 
imiquimod cream and 2.9 for the placebo (p=0.005).94 The results for the patient related 
cosmetic assessment for the five patients who were evaluated in the longer term between 39 
and 46 weeks was scored as 2.6 for the imiquimod cream and 1.5 for the placebo (p=0.309), 
and the investigator scores were 3.9 and 2.6 (p=0.191).94  
A summary of the studies examining moisturisers that have an effect on the cosmesis of the 
scar is outlined in Table 4-1 below. 
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Table 4-1: Summary of cosmesis outcomes of different moisturisers  
Moisturiser type Study / Design / Scar type How it was measured Effect 
Lumiere Bio-Restorative 
Eye Cream 
Murdock et al. 
2016100/RCT/Linear 
6 point scale developed by the authors, investigator assessment of 
wrinkles and texture.  
At week 14 10/20 treated eyelids looked better & 10/20 control eyelids 
looked better (p=1.00) 
   At week 10 60% (12/20) treated eyelids appeared better (p=0.039) 
 Murdock et al. 
2016100/RCT/Linear 
Subjects recorded which eye had a better scar appearance. 
Measured before treatment and again after.  
From 50% (10/20 scars) week 2 to 70% (14/20 scars) week 10, P=0.001 
Tacrolimus ointment Berman, Poochareon, et al. 
200545/case series / Keloid 
Scale 1 to 5, 1=excellent, 2=good, 3=satisfactory, 4=poor, 5=worse 
than the original keloid 
5/6 patients reported no or little improvement. Overall rated 4 (poor). 
Vitamin E Baumann et al. 199996/ 
RCT/Linear 
Unclear. Investigator and patient evaluated whether scar cosmesis 
was superior or no different for the Aquaphor®/control and study 
moisturiser (Aquaphor®  + Vit E)  
At 12 weeks: 90% (9/10) with investigator evaluation reported 
Aquaphor® was better or no different than Vit E. 100% (10/10) when 
patients evaluated reported Aquaphor® was better or no different than Vit 
E.  
Aquaphor® 
Vitamin E Jenkins et al. 200698/RCT/HTS Photographs pre-op and at each follow up and graded for ultimate 
cosmetic appearance by independent blinded observer.  
No significant difference in cosmetic appearance for any of the 3 creams 
(p value not reported). 
Aristocort® A 0.1%    
Aquatain    
Tretinoin cream 
(Retinoic Acid/Vit A) 
Dematte et al. 201179/quasi 
experimental/HTS 
Skin elasticity and resistance of skin biopsies measured with a 
mechanical oscillation analysis system.  
Decreased resistance 31.4% (p=0.003) and elastance improved 14.8% 
(p=0.047) 
Mederma®  
(onion extract gel) 
Chung et al. 
200697/RCT/Linear 
Physician evaluated overall cosmetic appearance if one half was 
better than another, VAS, 0=no difference to 10=significant 
difference. Phone interview with patients - rate if one scar better 
than other for overall cosmetic appearance and whether difference 
minimal, moderate or significant. Also asked if scars overall 
appearance poor, okay or excellent.  
86% (12/14) rated no difference between Mederma® and petrolatum. One 
subject reported Mederma® was better, one subject reported Petrolatum 
was better. T test p=0.9806, Wilcoxen test p=0.9583 
 Perez et al. 201056/RCT/HTS 
& Keloid 
VAS, 0=best to 100=worst overall cosmetic appearance. 
Investigator and subject rated.  
~25% improvement in keloid and HTS (not statistically significant, no p 
value).  
Petrolateum Chung et al. 200697/ 
RCT/Linear 
As above.  86% (12/14) rated no difference between Mederma® and petrolatum. One 
subject reported Mederma® was better, one subject reported petrolatum 
was better. T test p=0.9806, Wilcoxen test p=0.9583 
Scarguard®/HSE Perez et al. 201056/ RCT/HTS 
& Keloid 
VAS, 0=best to 100=worst overall cosmetic appearance. 
Investigator rated cosmesis.  
~67% improvement in keloid and HTS (p=<0.01) 
 Perez et al. 201056/RCT/HTS 
& Keloid 
VAS, 0=best to 100=worst overall cosmetic appearance. Subject 
rated cosmesis.  
~48% improvement in keloid and HTS (p=<0.01) 
Cetaphil®  
(used as placebo) 
Perez et al. 201056/ RCT/HTS 
& Keloid 
VAS, 0=best to 100=worst overall cosmetic appearance. 
Investigator rated cosmesis.  
~15% improvement in keloid and HTS (not statistically significant, no p 
value) 
 Perez et al. 201056/RCT /HTS 
& Keloid 
VAS, 0=best to 100=worst overall cosmetic appearance. Subject 
rated cosmesis.  
~58% improvement in keloid and HTS (p=0.01) 
Imiquimod 5% Berman, Frankel, et al. 200594 / 
RCT/Linear & HTS 
VAS, 0=best, 10=worst. Investigator assessment. At week 8: mean score for Imiqu. 4.4 & control 2.9 (p=0.005) 
   At wk 39-46 mean score for Imiqu. 3.9 & control 2.6 (=0.191) 
 Berman, Frankel, et al. 200594 / 
RCT/Linear & HTS 
VAS, 0=best, 10=worst. Subject assessment. At week 8: mean score for Imiqu. 3.2 & control 2.7 (p=0.140). At wk 39-
46 mean score for Imiqu. 2.6 & control 1.5 (p=0.309) 
No shading = no effect, green shading = positive effect, red shading = negative effect   




4.2 Scar parameters 
Scar parameters are measurements of the features of a scar which indicate scar activity or 
severity. The parameters are usually measured with standardised scales (Vancouver Scar 
Scale [VSS],74 Manchester Scar Scale [MSS],113 Patient and Observer Scar Assessment scale 
[POSAS]),73, photographs of scars, or visual analogue scales (usually created up by the 
author). They measure items such as scar height, pliability/thickness and 
colour/induration/erythema.  
Imiquimod 5% when compared to its vehicle cream as the control was found at week 8 to 
have worse outcomes for pigmentation (mean 0.8 for imiquimod group vs. 0.4 for vehicle 
cream, p=0.021), erythema (imiquimod 5.4 vs. vehicle cream 3.9, p=0.004) and induration 
(imiquimod 0.8 vs. vehicle cream 0.2, p=0.65).94 However, by the end of the study (week 39-
46) the two groups were close to being the same – pigmentation (imiquimod 1.8 vs. vehicle 
cream 2.1, p=0.122), erythema (imiquimod 1.8 vs. vehicle cream 2.1, p=0.753) and 
induration (imiquimod 0 vs. vehicle cream 0.4, p not available).94 However, imiquimod 
treated scars resulted in significantly improved mean scar scores, p<0.001, (Beausang scale: 
9.5-10.4, Strasser scale 2.7-3.3) when compared to no treatment or a petrolatum cream 
(Beausang scale: 14.8-16.2, Strasser scale 6.7-8.7).101  
Chung et al. (2006)97 reported no significant differences in redness/erythema when a 
physician evaluated the scar halves at the end of study assessment, week 12, when comparing 
Mederma®/onion extract to petrolatum (onion extract=0.39+/-0.36, petrolatum=0.16+/-0.13, 
p=0.3356). Similarly, the patient evaluated each scar half as not being any different from the 
other with regards to redness (onion extract=0.29+/-0.11, petrolatum=0.29+/-0.13, p=0.9142) 
which was treated with Mederma®/onion extract gel on one half and petrolatum on the other. 
A similar result occurred for the thickness of the scar assessed by the physician (onion 
extract=0, petrolatum=0, p=1.00).97 Earlier results at week 2 and week 8 were similar.97 
Similarly, another study found no difference in erythema between pre- and post-treatment of 
linear scars with Mederma®/onion extract after one month.104 However, in the same study 
the other group which applied Aquaphor® (petrolatum-based ointment) had a significant 
(p<0.01) reduction in erythema after one month.104  
Perez et al56 reported improvements from the use of Mederma® in four of the scar parameters 
measured. Values and percentages were taken from the graph and were an estimation of the 
true value. For Mederma® the mean percentage improvement of volume was 42% (p=0.01), 
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length 12% (p=0.02), width 16% (p=0.02) and induration 50% (p=0.03).56 It also showed 
improvement over the placebo (Cetaphil®) for induration, which was only 4%, (p<0.001) and 
pigmentation, which was worsened by 11% (no p value).56  
In the same study it was demonstrated that compared to baseline measures, scars treated with 
Scarguard®/HSE (0.5% hydrocortisone, silicone and vitamin E) resulted in a reduction in 
volume 40% (p=0.01), length 14% (p=0.02), induration 68% (p<0.01) erythema 74% 
(p<0.01) and pigmentation 62% (p<0.01).56  However, width showed 18% worsening (no p 
value).56 It also showed improvement over the placebo (Cetaphil®) for induration which was 
improved by only 4% (p<0.001), and erythema which only showed 1% improvement 
(p=0.01) with the Cetaphil® treatment.56 Cetaphil® did show a positive result but only for a 
mean reduction in volume of 32% (p=0.02).56 
When comparing Tretinoin cream 0.05% (retinoic acid/vitamin A) to a liquid silicone gel 
(Dermatix) on hypertrophic scars, no differences between the scar scale scores of the two 
groups were observed at any time. However when comparing to the control group which was 
no treatment at week 8 after removal of sutures there was a statistically significant difference 
(p<0.05) in the total scores of the Modified Vancouver Scar Scale (mVSS) between the 
treatment groups (Tretinoin score = 3.23, silicone score = 3.25, control group = 6.00).99 
Height was also reported to be significantly different (p<0.05) at (and beyond) week 8 from 
the treatment groups (Tretinoin score = 0.23, silicone score = 0.25) and the control (week 8 
score = 0.80). These scars were linear or hypertrophic scars.  
Tretinoin cream effects were also examined, with keloids of an average age of seven years 
(range one to 16 years) shown to significantly reduce the scar mean surface area from 
864mm2 (SD=1266.3) at week 0 to 392mm2 (SD=634.9) at week 12 (p=0.01).80 Mean 
volume/weight of the scar changed from 2.6gm (SD=3.9) at week 0 to 2.1gm (SD=3.0) at 
week 12 (p=0.04).80 Jansen De Limpens81 also reported Tretinoin cream reduced the colour 
and height of 13 out of 21 patients (13/21=61%), but the study reported this as 64% of 
patients and there was no report of statistical significance. This study was on hypertrophic 
and keloid scars.81 
Berman et al. (2005)45 measured the effect of Tacrolimus ointment on stable keloid scars and 
found no significant benefit with height and induration but reported some satisfactory, but not 
significant, improvement in erythema. The percentages of patients who benefited from using 
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the ointment varied from ~15% for improvements in volume to ~67% reporting 
improvements in erythema and induration (values obtained from graph).45  
Jenkins et al. (1986)98 comparing the effect of three creams – base cream, Aristocort® A 
0.1% and Vitamin E cream – used on post burn reconstructive surgery found there were no 
significant differences (p values not reported) between the groups for range of motion, scar 
thickness and graft size, and all were rated as having a good result. Similarly, in an evaluation 
of a basic moisturiser, Eucerin®, it was found that it also had some minor effects on scar 
pliability.61 It did not have an effect on pigmentation, elevation and vascularity, and it was 
reported to significantly (α<0.05) increase pliability by 10%.61  
A significantly positive effect (p<0.0025) (means not provided) was found in a study looking 
at the effects of adding putrescine to a base moisturiser and comparing it to the base alone on 
the scar parameters of erythema and height using a scale the authors designed themselves.48  
Use of a keratin gel (KeragelT®) when compared to aqueous cream on median sternotomy 
scars was found to result in more favourable scar scale scores (p>0.05) but was only 
statistically significant in a subset of subjects who initially had poor scarring.57 The mean 
scores for the keratin gel versus aqueous cream groups were: MSS 12.00 vs. 12.58, patient-
POSAS 16.70 vs. 17.85, observer-POSAS 15.00 vs. 16.55.57 In that subset of  poor scarring 
subjects, the MSS, patient-POSAS and observer-POSAS were statistically significant 
(p=0.025, <0.01 and 0.01), with scores in the treatment half being 12.22, 17.33 and 15.33 and 
in the control half being 14.22, 23.67 and 22.33, respectively.57  
Provase® was shown to have a significant impact on itch (see Section 4. 3), however it failed 
to demonstrate any difference in comparison to the base cream for measures on the VSS and 
Mexameter (data was not provided).58 
Demling and DeSanti46 investigated the effect of doxepin cream which contains doxepin HCl. 
It acts to block histamine receptors. Its use was compared to a group who were using oral 
antihistamines and a skin moisturiser that did not have antihistamine properties. Erythema 
was measured using the VSS. The scar is rated from 0 to 3, with 3 being red to purple in 
colour. Erythema was reported as being scored at 2 +/- 1 as the initial value and stayed the 
same for the standard care group, whereas the doxepin group showed a significant (p value 




An unpublished study on Bio-Oil® described percentages of subjects who reported 
improvements in their scars redness (65%), pigmentation (62%), width (42%), height (42%), 
and elasticity (46%), with 65% overall seeing improvement in their scars.82 There was no 
report on whether these numbers were statistically significant. Similarly the other 
unpublished study on Bio-Oil® reported results as the percentage of subjects who saw 
improvements in pigmentation (72%), pliability (67%), relief (67%) and thickness (61%), 
with 92% of subjects overall seeing improvement.83 There was also no report on whether this 
result was statistically significant. 




Table 4-2: Summary of scar parameter outcomes of different moisturisers 
Moisturiser type Study/design/scar 
type 
How it was measured Effect  
Imiquimod 5% Berman, Frankel et al. 
200594/RCT/linear & 
HTS 
VAS, 0 = best to 10 = worst. Induration.  Mean scores: Wk 8 - Imiqu. = 0.9, control = 0 (p=0.065). Beyond wk 8 - Imiqu = 0.4, 
control = 0.1 (p=0.078). Wk 39-46 - Imiqu = 0, control = 0 (p= N/A). 
  VAS, 0 = best to 10 = worst. Erythema.  Mean scores: Wk 8 - Imiqu. = 5.4, control = 3.9 (p=0.004). Beyond wk 8 - Imiqu = 2.6, 
control = 2.1 (p=0.467). Wk 39-46 - Imiqu = 1.8, control = 2.1 (p= 0.122). 
  VAS, 0 = best to 10 = worst. Pigmentary alterations.  Mean scores: Wk 8 - Imiqu. = 0.8, control = 0.4 (p=0.021). Beyond wk 8 - Imiqu = 2.6, 
control = 2.1 (p=0.467). Wk 39-46 - Imiqu = 1.8, control = 2.1 (p= 0.122). 
 Prado et al. 
2005101/RCT/linear 
Beausang scale evaluating colour & contour of scar assessed by 
blinded surgeon, nurse and surgeon.  
For all 3 assessors: treated scar scores - ranged from 9.5-10.4 & 2.7-3.3. Untreated scar 
scores - ranged from 14.8-16.2 6.7-8.7. All p <0.001.  
Mederma® (onion 
extract gel) 
Chung et al. 
200697/RCT/linear 
VAS, 0=absent to 10= severe. Patient evaluated redness & 
Physician evaluated scar redness and thickness for each of the 
scar halves.   
At 12 weeks differences between the 2 sides: Physician evaluation of redness (Onion 
extract=0.39+/-0.36, Petrolatum=0.16+/-0.13, p=0.3356), thickness (onion extract=0, 
Petrolatum=0, p=1.00). Patient evaluation redness (Onion extract=0.29+/-0.11, 
Petrolatum=0.29+/-0.13, p=0.9142).  
Petrolatum    
Mederma® (onion 
extract gel) 
Jackson & Shelton 
1999104/quasiexperiment
al/linear 
Patients rate erythema on a 5 point VAS. Photos taken. No statistical difference between pre- & post-treatment scores (p-value not provided).  
Aquaphor®  Patients rate erythema on a 5 point VAS. Photos taken. Reduction in erythema between pre- & post treatment scores (p<0.01) 
Mederma® (onion 
extract gel) 
  Reduction in volume (p=0.01), length (p=0.02), width (p=0.02) & induration (p=0.03). 
Showed improvement over the placebo (Cetaphil®) for induration (p<0.001) & 




silicone and VitE) 
Perez et al 
201056/RCT/HTS & 
keloid 
Scar volume measured with an alginate impression. Subjects 
and investigator rated the scar parameters volume, length, 
width, height, erythema, pigmentation on VAS 0-100, 0=best, 
100=worst. 
Reduction in volume (p=0.01), length (p=0.02), induration (p<0.01) erythema (p<0.01) 
& pigmentation (p<0.01).  Showed improvement over the placebo (Cetaphil®) for 
induration p<0.001), pigmentation (p<0.001) & erythema (p=0.01).  
Cetaphil® (as a 
placebo/control) 
  Mean reduction in volume (p=0.02) 
Tretinoin Cream Kwon et al. 
201499/RCT/HTS & 
Linear 
Modified Vancouver Scar Scale (mVSS) mVSS scores total significantly better for treatments compared to no treatment for 
weeks 8, 12 & 24. p<0.05.  
   mVSS scores comparison between Tretinoin and Dermatix (liquid silicone) - no 




Tape measure to measure area and volume assessed by taking 
impressions with dental moulages.  
Mean change in volume over 12 weeks 2.6 (SD=3.9) to 2.1 (SD=3.0) - reduced p=0.04. 
Mean change in size over 12 weeks 864 (SD=1266.3) to 392 (SD=634.9) - reduced 
p=0.01.  




Patient reported "improvement" also reported on colour, height 
and pigmentation. Objective result in "improvement".  
Subjective improvement in 14 patients - reported as 79%. Objectively 23/28 in the 
excellent, good and fair category - reported as 77%. 13/21 patients reported decreased 
discolouration and height - reported as 64%. No statistical significance calculated.**  
Continued next page  
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Tacrolimus ointment Berman, 
Poochareon, et al. 
200545/case series / 
keloid 
Volume of keloid measured by alginate impression.  
Induration determined by a set of rubber discs & recorded 
on VAS. Patient rated erythema.  
% of patients who benefited by improvements in diameter - 50-30%, height 50%, volume 
15%, erythema 67%, induration 67%. N=6. Percentages taken from a graph. Of those that 
showed improvement the percentage of change of the parameters measured that were greater 
than 40% were diameter, erythema, pain, tenderness (60% reduction) and pruritus (80% 
reduction). Not statistically significant. 
Aristocort® A 0.1% Jenkins et al. 198698 
/RCT/HTS 
Range of motion (ROM), average scar thickness at the edge 
of the graft and total surface area of the graft to measure 
contracture. 
ROM increased, scar thickness reduced, graft size increased but no significant difference 
between all 3 moisturisers.  
Vitamin E    
Aquatain (base cream)    
Eucerin® Phillips et al. 
199661/RCT/HTS & 
keloid 
VSS, scar size and volume measured with alginate 
impressions, photographs to record colour & texture.  
Pigmentation, elevation and vascularity remained unaffected (α=0.23).  
   Scar pliability increased 10% (α<0.05).  
Putrescine Dolynchuk et al. 
199648/RCT/HTS 
Photographs of scars evaluated and given numeric rating 
using scale where descriptors include erythema (no 
erythema-erythema) and irregularity (flat-nodular). 
The difference between the base cream only and base cream with putrescine was 
significantly lower scar ratings in the presence of the putrescine cream (p<0.0025) regardless 
of the order given. 




Manchester Scar Score (MSS) and Patient and Observer 
Scar Assessment Scale (POSAS). 
At 6 months scar scores for all patients were more favourable in the treatment group 
compared with the Aqueous group, not statistically significant, p>0.05. Keragel vs Aqueous: 
MSS 12.00 vs 12.58, patient-POSAS 16.70 vs 17.85, observer-POSAS 15.00 vs 16.55.  
Aqueous Cream   In the subgroup of patients with poor scars at 6 months there was an improvement with the 
keratin treatment that was statistically significant, p range <0.01-0.025. Keragel vs Aqueous: 
MSS 12.22 vs14.22, patient-POSAS 17.33 vs 3.67, observer-POSAS 15.33 vs 22.33.  
Provase® Nedelec et al. 
201258/RCT/HTS 
Modified Vancouver Scar Scale (mVSS) and Mexameter 
(quantifies erythema and melanin).  
The mVSS and Mexameter measurement of erythema did not vary significantly with time or 
treatment.  
Doxepin Demling et al. 
200246/quasi 
experimental/HTS 
VSS colour component only 0-3, 3=red/purple Erythema decreased from 2+/-1 to 0.5+/-0.5 over 12 weeks and was significantly (no p 
value) better than standard care group. 
Bio-Oil® MEDUNSA 200582 
/RCT/HTS & linear 
Changes in vascularity/redness, pigmentation, 
thickness/width, relief/height, & pliability/elasticity judged 
by the assessor.  
The percentages of subjects who report improvements in their scars: redness (65%), 





POSAS - pigmentation (observer), pliability (observer), 
colour (patient) and relief/height (patient). 
The percentage of subjects who saw improvements in: pigmentation (72%), pliability (67%), 
relief (67%) and thickness (61%). Statistical significance not reported.  
No shading = no effect, green shading = positive effect 
HTS = hypertrophic scar. VAS = Visual Analogue Scale. RCT = Randomised Controlled Trial  




4.3 Itch and pain 
Scars are notoriously itchy or pruritic (a more scientific term used for itch) and keloid scars in 
particular have been observed to be painful. Itch is a common outcome measure in studies on 
scars and treatment for scar management. In an analysis of risk factors for hypertrophic 
scaring, it was found that itch correlated with moisturiser use with hypertrophic scars but felt 
this may have been due to patients seeking relief from itch by applying a moisturiser.105 The 
authors found that there was a higher prevalence of hypertrophic scar formation in those 
patients who utilised scar treatment in the form of ointments, creams or lotions (p=0.038; chi-
square test, data not clarified).105 However, they also found that there was a significant 
difference between those with a hypertrophic scar and normotrophic scar regarding factors 
such as pain and itch (p=0.008; chi-square test, data not clarified).105  
Studies reporting itch as the primary outcome and demonstrating a positive effect include 
Demling et al. (2002),46 Nedelec et al. (2012)58 and Ogawa et al. (2008)55 Topical doxepin 
cream applied to the itchy area of a scar immediately decreased itch compared to the standard 
pharmacological approach, which was to take an oral antihistamine.46 The Doxepin cream 
reduced the itch from 5 +/- 2 (measured on a VAS of 0-10) to 1 +/- 1 by week 12, whereas 
itch in the standard care group reduced to 3 +/- 1.46 The differences between the doxepin and 
standard care group were significant at each time point of week 1, 8 and 12 but no p value 
was reported.46 
Nedelec et al. (2012)58 also found an improvement in itch in post burn scars with the use of 
Provase®, a protease containing moisturiser, when compared to the control, the base 
component only of Provase®. Due to the extent of the data produced the significant outcomes 




Table 4-3: Summary of itch outcomes of Provase® used with scars, from Nedelec et al. 
(2012).58  
Effect  Significance 
level 
Reduction in duration of itch  p<0.05 
Reduction in days per week participants experienced itch p=0.03 
Comparison between control and treatment group for number of times per day itch 
experienced from week 2.   
p=0.03 
Difference between baseline and week 2 for treatment group for number of times per day 
itch experienced 
p=0.03 
Mean itch TBSA when compared to baseline for treatment group at week 1 p=0.02 
Mean itch TBSA when compared to baseline for treatment group at week 2 p=0.04 
Mean itch TBSA when compared to baseline for treatment group at week 3 p=0.03 
Patients reporting itch as bothersome in treatment group at all times compared to 
baseline 
p=0.02-0.04 
Number of patients reporting itch as bothersome in treatment group compared to control 
group at week 4 
p<0.05 
Reduction in how annoying itch was in treatment group in week 3  p=.0.05 
Reduction in how annoying itch was in treatment group in week 3  p=0.03 
Reduction in how unbearable itch was in treatment group p=0.002-0.04 
When comparing treatment to control with how unbearable itch was at week 2 p=0.03 
TBSA: total body surface area  
 
Ogawa and Ogawa55 also found an improvement in itch but only after two months of 
treatment with Mugwort lotion where 11/14 (78.6%) of subjects showed improvement, 
compared to the control heparinoid ointment regions where 5/14 regions showed 
improvement (p=0.027). The authors also noted that most participants had previously tried 
systemic anti-allergenic drugs and found them to be ineffective.55  
Onion extract (Mederma®) was no different to petrolatum for the management of itch (at 12 
weeks mean scores onion extract 0.86 +/- 0.047 vs petrolatum 0.57 +/- 0.027, p=0.4533), 
burning and pain (same scores for both at 12 weeks: onion extract 0.043 +/- 0.02 vs. 
petrolatum 0.043 +/- 0.02, p=1.0000) on post-surgical scars.97 Jackson et al. (1999)104 also 
found Mederma® to have no statistically significant difference in the degree of itch reported 
by patients’ pre- and post-treatment with the cream (p value not provided). 
Base creams used in studies as a control or placebo can also generate results on their effect, 
or lack thereof, on scars. Aquaphor® was found to cause no statistically significant change to 
itch (scores and p value not provided). 104 Eucerin® was found to improve itch initially in 
hypertrophic scars and keloids but then it returned to near initial values.61 Rating of the itch 
on a VAS from 0-10 changed from 1.7 +/-3.1 in week 0 to 0.9 +/- 1.3 (week 2), 1.5 +/- 2.1 
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(week 4) to 1.4 +/- 2.11 and was significantly reduced, p<0.03.61 Scar pain also showed a 
similar pattern with VAS scale mean scores ranging from 1.4 to 0.7 but was reported to be 
somewhat reduced, p<0.08.61  
Tacrolimus ointment resulted in approximately 30% of patients reporting improvements in 
pain, approximately 60% reporting a decrease in tenderness, and approximately 80% 
reporting a decrease in pruritus but the result was reported as not statistically significant (p 
value not reported).45 The values were approximate as they were obtained from the graphical 
representation of percentage of patients reporting improvements in those symptom.45  
Tretinoin cream was reported to have improved pain in 14 patients out of 21 participants; 
statistical significance was not reported. This was reported as 79% but the actual calculation 
was 67%.81 
A summary of the studies examining moisturisers that had an effect on itch and pain 
experienced by patients with scars is outlined in Table 4-4.   
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Table 4-4: Summary of itch and pain outcomes of different moisturisers  
Moisturiser type Study / Design / Scar type How it was measured Effect:  
Doxepin Demling et al. 
200246/quasi 
experimental/HTS 
VAS 0-10 to quantify the degree of 
itch. 
Itch scores decreased from 5 +/- 2 to 1 +/- 1 in the Doxepin group compared to the standard care group which 
reduced to 3 +/- 1. Differences were significant at wk 1, 8 & 12, no p value.   
Provase®  Nedelec et al. 
201258/RCT/HTS 
VAS 0-10 itch intensities (before 
moisturiser and 30min after), 
description of itch during the past 
week based on units of duration and 
Questionnaire for Pruritus Assessment 
for Burn Survivors.  
See table 4-3 for summary of outcomes and statistical significance.  
   No difference between groups reporting their itch as annoying. For itch intensity at its worst or best and for 
general or local pain intensity - no significant difference between control and treatment (p value not given). 
Mugwort Lotion Ogawa & Ogawa 
200855/quasi 
experimental/HTS 
Survey of itch severity on a scale of 
0-4, 0 = no symptoms, 4 = severe itch.  
After 1 week: 40% (6/15) treated regions were improved, 21.3% (2/15) control regions improved.  No 
difference between treatment and control - p=0.107.  
At 2 months: 78.6% (11/14) treated regions were improved, 35.7% (5/14) control regions were improved. 




Chung et al 
200697/RCT/linear 
VAS rate itch, burning and pain from 
0 (absent) to 10 (severe) 
No statistical difference between Mederma® and petrolatum for itching burning and pain. At 12 weeks: 
itchiness - onion extract 0.86 +/- 0.047 vs petrolatum 0.57 +/- 0.027 (p=0.4533), burning – onion extract 0.043 
+/- 0.02 vs petrolatum 0.043 +/- 0.02 (p=1.0000), pain - onion extract 0.043 +/- 0.02 vs petrolatum 0.043 +/- 




Jackson & Shelton 
1999104/quasi 
experimental/linear 
VAS, 5 point scale, rate itch (no 
details of which features of itch) 
No statistical difference (no p value) between pre and post treatment with Mederma® when evaluating itch.  
Aquaphor®    No statistical difference (no p value) between pre and post treatment with Aquaphor® when evaluating itch.  
Eucerin® Phillips et al. 
199661/RCT/HTS & keloid 
VAS rate itch, pain. 0=none, 
10=unbearable.  
Scar itching mean scores significantly reduced (p<0.03): week 0: 1.7 +/-3.1, week 2: 0.9 +/- 1.3, week 4: 1.5 
+/- 2.1, week8: 1.4 +/- 2.11.  
   Scar pain mean scores somewhat reduced (p<0.08): 1.4 +/- 3.1, week 2: 0.7 +/- 1.43, week 4: 0.9 +/- 1.8, week 
8: 0.8 +/- 1.8. 
Tacrolimus 
ointment 
Berman, Poochareon et al. 
200545/case series/keloid 
Patients assessed their keloid for 
tenderness, pain and pruritus using a 
VAS.  
Around 30% of patients had improvement in pain. Of those that had improvements there was a 60% decrease 
in tenderness, 80% decrease in pruritus, results not statistically significant (p value not provided).  




Questionnaire (12 questions) 
completed by patients at completion 
of the study on improvement of pain 
and/or itching.  
Improvement in 14 patients (reported as 79% but number of participants is 21, e.g. should be 67%).   
No shading = no effect, green shading = positive effect 
HTS = hypertrophic scar, VAS = Visual Analogue Scale, RCT = randomised controlled trial  
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4.4  Trans-epidermal water loss and hydration 
There was only one study that reported TEWL comparing the moisturiser Alhydran against 
the performance of liquid silicone gels and silicone gel sheets.19 Hoeksema et al.19 used a tape 
stripping model to simulate a scar. They found that when compared to the control area, 
Alhydran performed significantly better (p<0.05, scores not provided) in terms of decreasing 
TEWL than Dermatix and Kelocote (liquid silicone gels). It also worked just as well as the 
BAP Scar Care gel (liquid silicone gel) in how occlusive it was and these both lasted longer 
than the other liquid silicones (p<0.05, scores not provided).19 They also demonstrated that 
Alhydran could increase hydration or water content of the skin to the same level as thin 
silicone gel sheets and Dermatix liquid silicone gel (but not Kelocote liquid silicone gel) but 
all values were the same one hour after removal.19 
 
4.5 In vitro outcomes 
Four studies examined the effects of moisturisers by using in vitro methods. Dematte et al. 
(2011)79 applied Tretinoin cream for one year on facial hypertrophic scars then obtained skin 
biopsies. They then examined resistance, elastance, collagen density and elastic fibre density 
of the skin biopsies. They found that there was a significant decrease in the mean values of 
resistance by 31.4% (p=0.003) and elastance by 14.8% (p=0.047), but there were no 
histological differences in the distributions of the extracellular matrix components between 
treated and untreated specimens.79  
Riaz at al.49 obtained samples of skin tissue from patients with hypertrophic or linear 
sternotomy scars. They found that increasing staining for type 1 procollagen (PCP1) 
correlated with increased macroscopic severity of scar (Spearman rank correlation coefficient 
= 0.604, p<0.001).49 However, after they applied Dermovate (steroid based) cream for seven 
days to scars and examined samples for a change in PCP1 staining, they found there was no 
effect on PCP1 staining when compared to control sites.49 
Ding et al. (2015)103 obtained fibroblasts from active keloid scars, mixed them with different 
concentrations of Wubeizi ointment and measured cell proliferation rates as a percentage of 
the control cells. They found with increasing concentration the inhibitory effect on 
proliferation increased with a significant difference between the high and low dose groups.103 
For example, the mean OD (optical density value) at 12 hours of the control group was 0.701 
+/- 0.104 compared to the high dose group which was 0.364 +/- 0.999 (p<0.01).103 At 24 
hours, the mean OD values for the control group were 0.554 +/- 0.130 compared to the high 
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dose group which was 0.233 +/- 0.041 (p<0.01), and at 36 hours the values for the control 
and high dose group were 0.413 +/- 0.033 and 0.126 +/- 0.018, respectively (p=<0.01).103 The 
inhibition was demonstrated by an increased percentage of fibroblasts in the S phase resulting 
in phase arrest and reduced numbers of dividing cells.103 The percentages of keloid 
fibroblasts for the control group was 37.32 +/- 2.93 compared to 60.35 +-/ 5.75 (p<0.01).103 
Jacob et al. (2003)31 also examined keloid scars. These were treated for two to eight weeks 
with imiquimod, or no treatment, and then the tissue was excised, the ribonucleic acid (RNA) 
extracted and complementary DNA (cDNA) probes synthesised.31 Findings demonstrated that 
there was a statistically significant alteration in the expression of the genes associated with 
apoptosis.31 Capsase 3 reduced from a mean value of 0.81 with the vehicle cream, to 0.05 
with Imiquimod (p<0.05). In addition, DNA fragment factor 45 was elevated in patients 
treated with Imiquimod (0.52) compared to those treated with the vehicle cream where the 
mean value was <0.01 (p<0.05).31 These results were felt to suggest a mechanism of action 
for imiquimod cream.   
A summary of the studies examining moisturisers that have an effect on in vitro outcomes of 




Table 4-5: Summary of in vitro outcomes of different moisturisers  
Moisturiser type Study/design/scar 
type 
How it was measured Effect 
Tretinoin Dematte et al 
201179/quasi 
experimental/HTS 
Measured elastance and resistance of excised skin samples post 
treatment using a mechanical oscillation analysis system.  
Resistance: decrease in mean values by 1.4% (p=0.003). 
Elastance: increased 14.8% (p=0.047)  
  Microscopically examined collagen and elastic fibre density.  No difference in the extracellular matrix between treated 
and untreated samples.  
Dermovate Riaz et al 
199449/quasi 
experimental/HTS 
Samples obtained after application of Dermovate, staining of tissues 
for type 1 procollagen (PCP1).   
No effect on PCP1 staining when compared to control site.  
Wubeizi ointment Ding et al 
2015103/quasi 
experimental/keloid 
Cell proliferation rates of fibroblasts subjected to different 
concentrations of the Wubeizi ointment.  
Increased concentration inhibits proliferation of fibroblasts. 
Control vs high dose group: At 12 hrs - 0.071+/-0.104 vs 
0.364+/-0.076, 24hr – 0.554+/-0.130 vs 0.233+/-0.041, 
36hr – 0.413+/-0.033 vs 0.126+/-0.018. All p<0.01. 
  Measurement of the DNA cycles at different Wubeizi concentrations.  Increased number of fibroblasts in the S phase arrest at 
higher concentration. Control vs high dose: 37.32+/-2.93 vs 
60.35+/-5.75 (p<0.01)  
Imiquimod 5% Jacob et al 
200331/quasi 
experimental/keloid 
RNA extracted to measure expression of genes associated with 
apoptosis. 
Significant change in expression of genes associated with 
apoptosis, Capsase 3 (reduced from 0.81 to 0.05) and DNA 
fragment factor 45 (increased from 0.52 to <0.01) when 
compared with control (p<0.05).  
No shading = no effect, green shading = positive effect 




4.6 Recurrence of excised keloids treated with 5% imiquimod – a meta-analysis  
All seven studies included in meta-analysis involved excising a stable keloid. A stable keloid 
was usually defined as one which had been present for more than one year and which had not 
had any treatment for the previous three months. Post excision, subjects were instructed to 
immediately begin application of imiquimod cream for six109, 111 or eight30, 106, 108, 110, 112 
weeks. All studies, except one,106 instructed subjects to apply the cream nightly or daily. 
Participants in the study by Berman et al. (2009)111 applied imiquimod for a period of six 
weeks: nightly for two weeks then three times a week for the next four weeks. As such, it was 
deemed that there was clinical homogeneity and meta-analysis was possible. In terms of 
methodological heterogeneity, the studies were different in their design, however all were 
included so as to provide the most comprehensive overview of the effect of imiquimod. To 
obtain this final determination, all studies were included in a meta-analysis forest plot (Table 
4-6), outlined below in Section 4.6.1. However, as there was variation in the data (see Figure 
4.1), further subgrouping was employed to determine whether the surgical technique (Section 
4.6.2) or the location of the keloid (Section 4.6.3) had effects on the outcome.  
 
4.6.1 Meta-analysis of all included studies in imiquimod group 
As mentioned above, all seven studies examined treated stable keloids for either six or eight 
weeks with a similar dosage by applying the cream daily.   
As shown by Figure 4-1, meta-analysis revealed that 39% (95% CI = 8.4% to 74.4%) of 
subjects had scar recurrence when using imiquimod post excision of a keloid scar. Based on 
the guide to interpretation of the I2 value described by Deeks et al. (2008),114 the I2 value of 
this meta-analysis of 87.5% (95% CI =75.7% to 92.2%) is greater than 75% and therefore 
indicates considerable heterogeneity. Essentially, given this heterogeneity, there is no 
confidence in the final effect size. 
Due to this variation, the results of this meta-analysis should not be considered as clinically 
informative but does not represent trustworthy information regarding the average number of 
participants who will have a recurrence of their keloid following treatment with imiquimod. 
To further investigate the heterogeneity seen in this meta-analysis, subgroup analyses were 




Table 4-6: Meta-analysis of all imiquimod studies 
Study Responding Total % weight 
(random) 
Berman et al. 2009 3 8 14.3 
Berman & Kaufman 
2002 
0 11 14.9 
Cacao et al. 2009 9 9 14.5 
Chuangsuwanich 2007 10 35 16.2 
Malhotra et al. 2007 3 3 11.7 
Martin-Garcia 2005 3 8 14.3 
Stashower 2006 0 8 14.3 
 
 
Figure 4-1: Meta-analysis of all imiquimod included studies, I2 (inconsistency) = 87.5% 
(95% CI = 75.7% to 92.2%) 
 
4.6.2 Meta-analysis – surgical technique 
On closer analysis of the studies, it was noted that some studies utilised different excision 
techniques and this may in turn have affected healing times and resultant scarring, as 
discussed in Section 1.3.2. As such, subgroup analysis of three30, 106, 112 studies that utilised 
primary excision with bilayer closure was possible. Meta-analysis of these studies is shown in 
Table 4-7 and Figure 4-2.   
81 
 
Similar to the results for the whole group (Figure 4-1), the forest plot in Figure 4-2 
demonstrates that a mean of 41.2%, (95% CI = 0 to 96.1%) of subjects who had a primary 
excision and bilayer closure would have a recurrence of their keloid. Statistically this is 
shown by the I2 value being 94.2% (95% CI = 86.4% to 96.6%), demonstrating that the results 
have considerable heterogeneity. Essentially, given this heterogeneity, there is no confidence 
in this final effect size. 
 
Table 4-7: Meta-analysis of studies utilising primary excision and bilayer closure as the 
surgical technique 
Study Responding Total % weight (random) 
Berman & Kaufman 2002 0 11 32.9 
Cacao et al. 2009 9 9 32.4 
Chuangsuwanich 2007 10 35 34.7 
 
 
Figure 4-2: Meta-analysis of studies utilising primary excision and bilayer closure as the 
surgical technique, I2 (inconsistency) = 94.2% (95% CI = 86.4% to 96.6%) 
 
There were four studies108-111 that utilised surgical methods where the keloid was excised by 
shaving or tangential excision leaving an open wound to heal by secondary intention (Table 4-
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8). The imiquimod cream was then applied to the wound despite it still being open. These 
studies are represented on a forest plot (Figure 4-3). The meta-analysis of those studies 
demonstrates that 36.9% (95% CI = 1.9% to 81.2%) of subjects had recurrence of their 
keloids. As these studies produced an I2 value of 78.1% (95% CI = 0.5% to 90%), the results 
have considerable heterogeneity. Essentially, given this heterogeneity, there is no confidence 
in this final effect size. 
 
Table 4-8: Meta-analysis of studies utilising shaving or tangential excision that result in 
healing by secondary intention 
Study Responding Total % weight (random) 
Berman et al. 2009 3 8 26.4 
Malhotra et al. 2007 3 3 20.8 
Martin-Garcia 2005 3 8 26.4 
Stashower 2006 0 8 26.4 
 
 
Figure 4-3: Meta-analysis of studies utilising shave/tangential excision that result in 





4.6.3 Meta-analysis – location of keloid 
Some authors of these included studies noted that body location may have had an effect on the 
outcome of recurrence of a keloid post excision. Certain areas of the body under tension may 
be prone to recurrence (such as the chest) whilst those areas of low tension (such as the 
earlobe) may be prone to less recurrence (see Section 1.4.3). To further investigate whether 
this is a reasonable assumption, those studies that specified earlobe keloids were plotted 
together (Figure 4-4), and studies on keloids in other locations, mostly on the trunk, were 
plotted together (Figure 4-5).  
Table 4-9 and Figure 4-4 collate and plot the studies which examined earlobe keloid excision. 
An assumption was required for the Berman and Kaufman30 study where there were initially 
12 patients with 13 keloids – 12 earlobe keloids and one back keloid. Two patients were lost 
to follow-up resulting in 10 patients with 11 keloids. It was assumed that the two patients lost 
to follow-up had single earlobe keloids and that the final 10 patients therefore comprised 10 
earlobe keloid and one back keloid. Although they had a variety of locations in their study, 
Chuangsuwanich and Gunjittisomrarn106 did report a 1/22 recurrence rate for those keloids on 
the earlobes. The other two studies108, 109 included subjects with only earlobe keloids.  
The meta-analysis of earlobe keloid subjects (Figure 4-4) shows that 5.4% (95% CI = 0% to 
21.7%) of these patients showed recurrence of keloids on the earlobe with post-operative 
imiquimod application. The I2 value is less than the previous forest plots, with a value of 
52.9% (95% CI = 0% to 82.6%), demonstrating a greater degree of similarity but still having 
substantial heterogeneity.  
 
Table 4-9: Meta-analysis of earlobe keloids 
Study Responding Total % weight (random) 
Berman & Kaufman 2002 0 10 24.1 
Chuangsuwanich 2007 1 22 32.8 
Martin-Garcia 2005 3 8 21.6 





Figure 4-4: Meta-analysis of earlobe keloids, I2 (inconsistency) = 52.9% (95% CI = 0% to 
82.6%) 
 
A meta-analysis of recurrence of keloids located in other areas of the body under higher 
tension than the earlobe resulted in generation of a forest plot (Table 4-10 and Figure 4-5). Of 
the studies included, Berman et al111 did not report the exact location of keloids but did report 
them as being in many different locations. Berman and Kaufman30 had one back keloid which 
did not recur and this was included in the meta-analysis. On examination of the results 
reported by Chuangsuwanich and Gunjittisomrarn,106 it was found that there was recurrence 
of 5/6 keloids on the chest,  4/7 keloids on the neck and shoulder,  resulting in 9/13 
recurrences for this study in the areas other than the earlobes. The other included studies 
investigated keloids on the chest110, 112 and shoulder.112  
The meta-analysis shows that 76.75% (95% CI = 36.1% to 100%) of all subjects had 
recurrence of their keloids on other areas of the body, particularly the trunk, with the use of 
imiquimod post-operatively. However, as the I2 value is 70.5% (95% CI = 0% to 86.4%), this 
represents substantial heterogeneity. Essentially, given this heterogeneity, there is no 





Table 4-10: Meta-analysis of keloids in other (not earlobe) locations on the body 
Study Responding Total % weight (random) 
Berman et al. 2009 3 8 23.1 
Berman & Kaufman 2002 0 1 10.7 
Cacao et al. 2009 9 9 23.7 
Chuangsuwanich 2007 9 13 25.4 
Malhotra 2007 3 3 17.1 
 
 
Figure 4-5: Meta-analysis of keloids in other (not earlobe) locations on the body, I2 
(inconsistency) = 70.5% (95% CI = 0% to 86.4%)  
 
4.7 Adverse events 
Adverse events were frequently reported in studies examining moisturiser effects on scars. 
Even basic moisturisers such as Aquatain can elicit adverse reactions in 6% of participants.98 
Eucerin® caused increased itching in one participant out of ten in the moisturiser group.61 
Berman et al. (2005) also reported two out of 18 participants in the control group who were 
given the ‘vehicle cream’ had adverse reactions.94 Nedelec et al. (2012), when looking at itch 
and pain, reported that the base moisturiser resulted in an adverse event: two participants 
experiencing increased pain and itch. This helped to strengthen the argument for the effect of 
itch by the treatment moisturiser (Provase®) as they had no such adverse events.58  
One person stopped using the Mugwort lotion because it caused a cold sensation.55 
Interestingly the vitamin E addition to a basic moisturiser resulted in a large proportion of 
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participants – 33%96 and 20%98– having reactions. However, these adverse events may have 
been related to the type of vitamin E added to the base cream, that is, oral vitamin E capsule 
contents were physically added to the cream. Doxepin resulted in mild and transient 
somnolence (drowsiness) in 15% of patients which resolved after two to three days with 
continued use and one patient had a localised skin reaction and was removed from the study.46  
The studies investigating the effects of imiquimod 5% on scar parameters and cosmesis 
appear to consistently report participants needing a rest period at around week 2-3.94, 101 The 
studies included in the imiquimod group for meta-analysis also reported the same issue. 
Tacrolimus ointment had a high incidence of causing an adverse reaction as one patient was 
removed from the study for flu like symptoms, itch, burning and pain at the treatment site.45 
In addition, five out of the six participants experienced localised itch for up to two hours for 
the first few days of treatment.45  
Of the topical steroids, putrescine caused only one person to have a rash and withdraw and 
13.5% of participants in the Aristocort® A 0.1% study had adverse reactions including striae 
and delayed healing of open areas but it was reported the reactions resolved with discontinued 
use and removal from the study.48, 98 The use of Mederma® (topical onion extract) resulted in 
three (50%) of subjects discontinuing the study when it was being evaluated for its 
effectiveness on scars post skin cancer removal.104 However there was only one subject with 
an acneiform-like eruption at the site of application in another study.56 
Tretinoin cream resulted in contact dermatitis in two out of nine participants which resulted in 
them abandoning the study.80 It also caused a burning sensation in three out of seven 
participants during its first week of use but resolved without any special treatment.99 It 
resulted in half of the patients in another study needing to reduce their application frequency 
after redness and/or scaliness of the skin.81 In the longer term study of tretinoin cream, one 
third of the subjects exhibited temporary signs of dermatitis but continued on without any 
recurrence after a one-week rest period.79 In addition, in the same study, three patients had 
hyperpigmentation and one exhibited mild telangiectasis (dilation of capillaries).79   
In the study testing Lumiere Bio-Restorative Eye Cream, three subjects withdrew due to 




5. Discussion and conclusions 
This chapter discusses the results of the systematic review presented in the preceding 
chapters. To aid clinicians and consumers to apply the results clinically, the effects of 
moisturisers are grouped according to the cost and availability of the product. This review has 
a number of limitations that impact on the conclusions that can be drawn; these limitations 
include the quality of the included studies and the means and methods used to measure 
outcomes. Suggestions for further research especially for common or basic moisturisers are 
outlined.  
 
5.1 Effect of moisturisers on outcomes 
The results of this systematic review provide no definitive evidence to inform a decision 
about which moisturiser has outstanding overall effectiveness to manage scars. Rather, to 
obtain a specific outcome, the clinician may recommend a specific moisturiser. Conversely, 
the results of this systematic review can inform the clinician as to which moisturisers are not 
effective.  
Patients frequently have questions or opinions about a product they have seen advertised or 
have heard about from other clinicians, family and friends. The clinician will consider and 
discuss with the patient many factors such as the scar size, the effect on the person’s 
emotional and physical wellbeing, and the cost of various options, and subsequently formulate 
a recommendation. One of the most significant factors influencing a service (if a product is 
provided) or the consumer’s choice (if they are required to self-fund) is the cost and 
availability of a product. Therefore, the clinician should be armed with the knowledge 
outlined below to guide their decision when selecting a product. 
 
5.1.1 Treatments with an effect 
The moisturisers that have a significantly positive effect on cosmesis includes Lumiere Bio-
Restorative Eye Cream, Tretinoin, Scarguard®/HSE, and Cetaphil® (see Table 4-1).  The 
moisturisers which have a significantly positive effect on scar parameters include 
Scarguard®/HSE, Cetaphil®, Tretinoin, Eucerin®, putrescine and Doxepin (see Table 4-2). 
Those that have a significantly positive effect on itch and pain include Doxepin, Mugwort 
Lotion and Eucerin® (see Table 4-4). Tretinoin and Wubeizei ointments were shown to have 
a significant positive effect on in vitro outcomes (see Table 4-5). Although imiquimod also 
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had a positive effect, it had not been included in the group to be recommended as it had no 
effect on many of the other outcomes as mentioned above.  
Moisturisers that can be recommended are presented according to availability and cost. This is 
clinically relevant for clinicians and consumers to determine which is best for their needs. A 
summary of the recommendations, outcomes and scar types is contained in Table 5-1 at the 
end of this section.  
 
5.1.1.1 Prescription only moisturisers that have an effect on scars 
There were only two prescription-only moisturisers that can be recommended as they had a 
statistically significant beneficial effect on scars: putrescine (Fibrostat®) and Doxepin. 
Putrescine may be beneficial in reducing the parameters of hypertrophic scars but further 
studies are needed with clear descriptions of the study design and subjects. Despite the author 
reporting that a total of 128 patients had been treated with topical putrescine and minimal 
adverse events (one person with a rash),48 this treatment has not been investigated in any 
further studies, nor become part of current regular management of scars. A search of Fibrostat 
via Google (May 2018) revealed that a clinical trial had been registered for December 2017 at 
the same location (University of Manitoba) as the original study but no results have been 
posted.115 There is also an article suggesting that recruitment was occurring in 2004 for 
another study by the same author of the original study but this did not proceed to 
publication.116 However, a website (www.fibrostat.com) was located, containing documents, 
one of which is a word document of a paper delivered in 2016. This contains minimal detail 
on the results an unpublished RCT examining the effect of Fibrostat® on post breast 
reduction scars. The reported results were significantly favourable when subjectively reported 
by patients and objectively measured by durometry (measures hardness) but not when 
measured by a scar scale (MSS). Cost data could not be obtained for this prescribed 
moisturiser, however, considering it contains an active drug it is likely to be costly and can 
therefore only be recommended for small cosmetically sensitive hypertrophic scars.  
Topical Doxepin appeared to be more effective than an oral antihistamine in the reduction of 
burn scar itch and it was also shown to reduce erythema of the scars. However, as mentioned 
previously (section 3.5.1) patients were six weeks to three months post burn when the itching 
was at its worst and this period was the point of highest scar activity and erythema.46 There is 
also potential for scars to naturally begin to reduce in activity and therefore in erythema and 
itch intensity. Topical Doxepin may be recommended to reduce early burn scar itch but a 
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study utilizing a control group would be recommended to clarify the significance of its effect 
in comparison to a basic moisturiser.  
 
5.1.1.2 High cost/over the counter moisturisers that have an effect on scars 
There were seven high cost/over the counter moisturisers which showed significantly positive 
effects on scars. They are tretinoin/retinoic acid/vitamin A, Wubeizei, Lumiere Bio-
Restorative Eye Cream, Scarguard® HSE, Provase®, Mugwort Lotion and Alhydran. 
Considering their high cost, they are unlikely to be recommended for large scars but would be 
more suited to smaller, cosmetically sensitive scars.  
There were four studies that examined the effects of tretinoin/retinoic acid/vitamin A on 
scars.79-81, 99 Three studies used the moisturiser at a concentration of 0.05%, whereas Kwon et 
al. (2014)99 used the 0.025% variation of the moisturiser. They found that patients with 
postoperative wounds had no difference in scar scale scores when comparing the scores to 
those subjects that used Dermatix, a liquid silicone gel.99 Hoeksema et al. (2013)19 also 
measured the effects of Dermatix. They reported that Dermatix reduced TEWL and hydrated 
the stratum corneum (however, Alhydran and a silicone gel sheet were more effective in this 
regard).19 As a result, the 0.025% variation of tretinoin may have been no more effective than 
Dermatix, and both were inferior to Alhydran. Tretinoin can be recommended for small (due 
to cost) cosmetically significant hypertrophic or post-surgical scars which cause cosmetic 
concerns due to tightness or contracture of the scar. However, patients should be advised 
regarding the risk of hyperpigmentation and that continued use would also be required to 
ensure clinical gains. 
Wubeizi ointment contains the ingredient Wu Bei Zi, a tannin produced by a tree when 
infected by aphids. The author referenced his own previous study (not in English) in the 
introduction to claim that Wubeizi ointment was effective in treating keloids and therefore 
completed a study to examine the effects of different concentrations of Wubeizi ointment on 
keloid fibroblast proliferation and demonstrated significant effects.103 Wubeizi cannot be 
strongly recommended for the management of keloid scars without further investigation of its 
effects on scars and any adverse events.  
Eyelids treated with Lumiere Bio-Restorative Eye cream was found to have a better cosmetic 
outcome than its control (no moisturiser) as they reached maturity earlier but only in the early 
stage of the study (week 10). At completion of the study, just four weeks later, there was the 
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same improvement in all of the eyelid scars.100 As the patients were not applying a control 
moisturiser they may have been biased in their ratings of the cosmetic effect. Considering the 
cost and the additional four weeks required to achieve the same outcome, Lumiere Bio-
Restorative Eye Cream is not recommended for patients with new post-operative linear scars.  
Scarguard® HSE did show significant improvement in investigator and subject rated cosmesis 
of keloid and hypertrophic scars.56 Hypertrophic and keloid scars also had a reduction in 
volume, length, induration, erythema and pigmentation over the 16-week period of the 
study.56 Scarguard® HSE showed improvement over the placebo (Cetaphil®) for induration, 
pigmentation and erythema.56 However, as Scarguard® HSE is not available and the study 
had a mix of scar types and small numbers in each group it is not strongly recommended as a 
consideration for scar treatment.  
The study on Provase® was reported as being a pilot study, however, there was an extensive 
data set that allowed the authors to conclude that the treatment group was having the itch 
cycle interrupted compared to the control group.58 Provase® can be recommended for 
reducing itching of post burn scars in the early phase (one to three months). However, more 
data is needed to determine whether it is effective in scars more than three months post injury. 
The authors also acknowledged that the study was not statistically powered and was only 
conducted over a four-week period.58 Had the study been extended, the following could have 
been determined: if the effect had worn off, if the itch had returned or if the itch had been 
resolved. In addition, it would be of interest to establish if the itch returned after cessation of 
application.  
Although Ogawa et al (2008)55 found no difference in severity of itch between treatment and 
control (a heparinoid ointment – no further details). After one week they did find a difference 
between the groups after two months of applying the lotion to hypertrophic burn scars. This is 
in contrast to the study by Nedelec et al. (2012)58 on Provase® who noted a much more rapid 
response to the moisturiser. The authors concluded that topically applied antihistamines may 
be more effective than systemic ones as many of the participants had trialled systemic 
antihistamines with no effect.55 Mugwort lotion may be effective in reducing itch of post burn 
hypertrophic scars but the effect may take anywhere between one week and two months. 
Other side effects or adverse events were not clearly outlined and require clarification before 
recommending this product.  
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Alhydran was included in the study by Hoeksema et al. (2013)19 as it had reportedly been 
used by patients at the author’s clinic, and the patients reported that they preferred it over 
other moisturisers. The study was based in Belgium and included products, except Kelocote 
and Dermatix, not available in Australia. It has only been recently (May 2018) that Alhydran 
has become available in Australia. The effect of Alhydran on TEWL and hydration of tape 
stripped skin of normal subjects was examined.19 The authors compared the outcomes to those 
of silicone gel sheets and the liquid silicones, including Dermatix and Kelocote, that are also 
available in Australia.19 This first study of its kind demonstrated that Alhydran was able to 
reduce TEWL more effectively than Dermatix and Kelocote.19 Alhydran also increased 
hydration as effectively as a thin silicone gel sheet and Dermatix, but Kelocote was not as 
effective as either of these.19  
The measurement of TEWL is an important outcome measure in the management of scars. It 
has been proposed that the effectiveness of silicone gel sheets is attributed to their capacity to 
reduce and normalise the rate of TEWL18, 117 which is elevated in hypertrophic and keloid 
scars.17, 18 Alhydran can hydrate and reduce the TEWL of skin that has had its barrier function 
of the stratum corneum disrupted so that there is a high rate of TEWL such as that which 
occurs in scars. As a result, it can be recommended to patients with hypertrophic and keloid 
scars. The Hoeksema et al. (2013) study is also useful for those that utilise the products 
Dermatix and Kelocote as they would now have to question their effectiveness.  
 
5.1.1.3 Low cost/over the counter moisturisers that have an effect on scars 
In some studies, moisturisers that were included as controls showed they could also have a 
significant effect on improving scar outcomes. These included Cetaphil® and Eucerin®, in 
particular. These moisturisers are readily available from retail outlets and are of low cost (as 
outlined in Section 1.6.1.3) and are therefore most suited to those patients with a large scar 
surface area such as major burns.  
Cetaphil® was shown to have a significantly positive effect on reducing scar volume and 
subject rated cosmesis but the improvement in cosmesis was not significant when measured 
by the investigators.56 Considering the low cost and ease of availability of this moisturiser, it 
may well be that this basic moisturiser may have a positive outcome on the cosmesis and scar 
parameters of hypertrophic and keloid scars. Nonetheless, the quality issues identified in this 
study makes it difficult to recommend Cetaphil® with any confidence.   
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Eucerin® is commonly recommended to burn patients in the US.5 In a study aimed to 
examine hydrocolloid dressings, Eucerin® as a control was found to not have a significant 
effect on scar parameters but reduced itch and pain, and increased scar pliability.61 However, 
the itching was initially reduced in this study but later stabilised to near initial values.61 As 
Eucerin® is likely to be recommended to a large number of burn scar patients, further well-
structured studies would be of benefit. For the interim though it is reasonable that it continues 
to be recommended as part of scar management in the US. 
 
5.1.1 No or limited effect 
Moisturisers that cannot be recommended to have a statistically significantly positive effect 
on cosmesis include Imiquimod, Tacrolims ointment, Aristocort® A 0.1%, Mederma®, 
vitamin E, Aquatain, Aquaphor® and petrolateum. The moisturisers which do not have a 
significantly positive effect on scar parameters includes Imiquimod, Tacrolimus ointment, 
Aristocort® A 0.1%, Mederma®, Keratin Gel, Provase®, Bio-Oil®, Vitamin E, Aquatain and 
Petrolateum. Mederma®, Aquaphor®, Tacrolimus and Tretinoin do not have a significant 
effect on itch and/or pain. Dermovate was the only study investigating in-vitro outcomes that 
showed no significant effect.  
The following section outlines the moisturisers that do not have a statistically significant 
effect grouped according to the cost and availability as outlined earlier (see Section 1.6.1). 
5.1.2.1 Prescription only moisturisers that do not have an effect on scars 
Imiquimod was the only moisturiser found to have a negative effect on cosmesis in 
comparison to control.94 However, it is difficult to ascertain if a 1.5 point difference in the 
mean score between control and imiquimod on a VAS is clinically significant. This result was 
measured at week 8 of the study and the difference between the groups became insignificant 
later.94 Although Berman et al. (2005)94 reported no difference when comparing imiquimod to 
a control moisturiser when measuring induration, erythema and pigment, Prado et al. 
(2005)101 did find differences in the colour and contour of scars. They both examined post-
surgical linear scars but Berman et al. (2005)94 implemented a maximum 14-week time frame 
and the Prado et al 101 study had a 24-week timeframe. The Prado et al. (2005)101 study had as 
a control no treatment whereas Berman et al. (2005)94 used vehicle cream as a control. As 
Berman et al. (2005)94 found no difference between the two groups and Prado et al. (2005)101 
did, it may well be that the vehicle cream alone had some effect and not necessarily the 
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imiquimod within the cream. Therefore, Imiquimod cannot be recommended to improve scar 
cosmesis and scar parameters.   
For keloids, imiquimod application post excision did not appear to have an effect on 
recurrence rates and is therefore not recommended as a treatment option. Imiquimod 
application post excision of a keloid results in highly variable recurrence rates (see Section 
4.6). These highly variable rates of recurrence remained even when subgroup analysis 
investigating differing surgical technique was performed. Some of the variation observed 
appeared to be explained when data were analysed according to location of the keloid; the 
recurrence for earlobe keloids was 6.2% compared to the other areas of the body (particularly 
the trunk) which was 69.1%. This is a different result to a recent meta-analysis42 which 
calculated recurrence rates as 13.6% (earlobes) and 24.9% (all areas) as discussed in Section 
1.6.1.1. In Shin et al (2017),42 despite the authors’ claim that a strength of their meta-analysis 
was that they conducted a thorough search, it only located and included four of the seven 
studies included in this review. Investigating subgroups based on body location of the scar is 
supported by the clinical and documented observation that earlobe keloids have a lower 
recurrence rate compared to other areas of the body, particularly the chest.118 There is some 
evidence that the tension in the wound bed determines the type of scar at different body sites, 
for example, there is high tension at the chest and low tension on the skin at the earlobe post 
excision of a keloid.119  
AristocortA 0.1%®  cream which has Aquatain as a base was compared to Vitamin E added 
to Aquatain, and to Aquatain alone, on burns scar reconstructions.98 There was no difference 
between all three groups for all scar outcomes of cosmesis and scar parameters.98 Topical 
Aristocort A 0.1%® cannot be recommended for scar cosmesis and scar parameters as it 
appears to have no effects and comes with a raft of potential side effects that would 
exacerbate a negative scar outcome. Similar to Aristocrt A 0.1%®, Clobetasol proprionate 
0.05%/Dermovate is a topical corticosteroid. It is not recommended for hypertrophic scars as 
it has no effect and is accompanied by significant local and systemic side effects.  
Finally, in the prescription group, Tacrolimus ointment cannot be recommended as a 
treatment that has any effect on keloid scar cosmesis, scar parameters, itch or pain.  
5.1.2.2 High cost/over the counter moisturisers that do not have an effect on scars 
Mederma® was examined in a total of three studies56, 97, 104, two of which found no significant 
effect on cosmesis.56, 97 Chung et al. (2006)97 found no difference between Mederma® and 
Petrolateum and the poor quality study by Perez et al (2010)56 found no significant 
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improvement with Mederma®. Considering the high cost of Mederma® and that it appears no 
more effective than petrolatum, it would not be value for money. The low cost petrolatum is 
no different in its effectiveness to the more costly Mederma®. However, neither have strong 
data to back any confident recommendations for or against using them for managing cosmesis 
and scar parameters of linear scars.  
Considering the methodological quality of the Bio-Oil® studies (see section 3.5.1) where the 
studies were self-funded and not published in peer review journals, and where the 
manufacturer would not release further details about these studies, there is no adequate 
evidence to indicate that Bio-Oil® has an effect on scar parameters and therefore cannot be 
recommended at this point in time. It was also interesting to note that the company website 
reports that the formulation ‘contains the breakthrough ingredient PurCellin Oil™’,52(para 1) yet 
this ingredient is not listed in the list of ingredients53 on the same website. Studies 
implementing an appropriate control group, objective outcome measures and careful subject 
selection are needed to clarify the effect of this well marketed scar lotion.  
When the authors examined all results on the effects of keratin gel (Keragel T), they did not 
identify a significant difference between the treatment and control groups.57 It was only when 
they isolated the ‘poor’ scars that the treatment group obtained significance over the control. 
However, aqueous cream as the control may not have been the wisest choice due to concerns 
about its effects on normal skin. Due to the ambiguity of the results, keratin gel cannot be 
recommended. A repeat of the study with an alternative control moisturiser and a larger 
number of subjects to enable a strong conclusion would be beneficial.   
5.1.2.3 Low cost/over the counter moisturisers that do not have an effect on scars 
It was interesting to note that despite the widespread acceptance59 of vitamin E, there was no 
significant positive effect on the moisturisers containing it. The results of this systematic 
review indicate that vitamin E’s reputation as a beneficial addition to a moisturiser is not 
warranted. It was also noted that the addition of Vitamin E from an oral capsule to a base 
moisturiser might have been the reason for the high occurrence of adverse events.96 Therefore, 
patients should be advised to not add oral vitamin E capsules to a basic moisturiser.  
A systematic review examining the role of vitamin E in scar management was found after this 
author’s systematic review was completed.120 In this review, Tanaydin et al. (2016)121 
included six studies, among which were Baumann et al. (1999),96 Jenkins et al. (1986),98 and 
Perez et al. (2010)56 which are all in the current systematic review. Also included was 
Zampieri et al. (2014)122 which was excluded from the current systematic review as the 
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ointment containing vitamin E (Lipogel) was applied prior to surgery (for 30 days) and from 
day 1 post-operatively, and therefore may have had an effect on wound healing rather than 
scar development as such. The second study not included in this systematic review was Khoo 
et al. (2011)123 This study could not be located in the searching as it does not refer to the 
topical vitamin E, in the form of tocotrienol, as being a moisturiser except for once in the 
description of how it was prepared where it was referred to as being a cream. They found 
there was no difference between the vitamin E group and the placebo when the creams were 
applied to early post-surgical linear scars. The third study not included in the current 
systematic review was Palmieri et al.(1995)124 who investigated the effect of adding vitamin E 
to silicone gel sheets. Therefore, it was not a study that investigated the effect of a moisturiser 
on a scar. Finally, Tanaydin et al (2016)121 also concluded that there was insufficient evidence 
that vitamin E had a beneficial effect on scars to justify its widespread use.   
Baumann et al (1999)96 used Aquaphor® as a control and base moisturiser to add vitamin E 
from supplement capsules. The Aquaphor® alone performed better through the early stages of 
the study likely due to the vitamin E side of the scar having a high incidence of local 
reactions. The final outcome at 12 weeks was predominantly no difference. However, this 
study lacked detail on cosmetic measurement, only asking if one side was better or no 
different to the other. Additionally, being linear scars, after 12 weeks, all scars are likely to 
look similar whether they have treatment or not. Jackson and Shelton (1999)104 utilised 
Aquaphor® as a control moisturiser when examining the effects of Mederma® (onion extract 
gel). They reported the Aquaphor® group to have a significant reduction in erythema scores 
but it had no effect on itch in pre and post scores of linear scars.104 However, there were 
methodological issues with this study including small sample sizes, insufficient information 
on the scar age and subject characteristics. Aquaphor® may be utilised to reduce erythema of 
linear scars. However, due to the low quality and lack of detail of the study it cannot be 
recommended with any confidence.  
A search of the internet yielded only a material safety data sheet from 2007 but no further 
information on the availability of Aquatain that was utilised by Jenkins et al.(1986)98 as a 
placebo cream and as a base to add to Aristocort® 0.1%. As this study was conducted in 
1986, it is suspected that this moisturiser is no longer available. The study did not provide any 
details on the composition of this moisturiser to enable comment on its effectiveness or allow 
comparisons with other moisturisers.  
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Petrolateum was utilised in two studies as a control for comparison against Mederma®97 (as 
mentioned above) and imiquimod.101 The low cost petrolatum is no different in its 
effectiveness to the more costly Mederma®. There is inadequate data to enable confident 
recommendations to be made for or against petrolatum for managing cosmesis of linear scars.  
Although aqueous cream was included as a control moisturiser in one study,57 its effects alone 
were not measured as they were for some other control moisturisers. However, considering 
that previous studies on aqueous cream demonstrated that it increased TEWL in healthy skin 
and decreased the thickness of the stratum corneum62, 63 (see Section 1.3), this product cannot 
be recommended. Aqueous cream should not be utilised as a control moisturiser in studies 
examining the effectiveness of a moisturiser on scar outcomes. 
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Outcomes Scar types 
C SP I&P IV T&H Linear Hyper-
trophic 
Keloid 
Prescription only          
Imiquimod 5%  -         
Tacrolimus Ointment -         
Doxepin/Prudoxin ++         
Putrescine (Fibrostat®) ++         
Clobetasol proprionate 0.05%/Dermovate  -         
Aristocort® 0.1% -         
High Cost OTC          
Tretinoin cream/retinoic acid/vitamin A (0.05%)  +++         
Bio-Oil® -         
Wubeizi +         
Lumiere Bio-Restorative Eye Cream +         
Mederma®/onion extract -         
Scarguard®/HSE +         
Keratin gel/KeragelT® -         
Provase® +++         
Mugwort Lotion +         
Alhydran ++++      * * * 
Low cost OTC          
Vitamin E -         
Aquaphor® -         
Cetaphil® ++         
Eucerin® ++         
Aqueous -         
Petrolateum -         
Aquatain -         
Recommendations:  
++++ Able to recommend 
+++ recommend but with minor reservations  
++ recommend but with moderate reservations  
+ recommend but with major reservations  
- not able to recommend  
Outcomes: C = cosmesis, SP = scar parameters, I&P = itch and pain, IV = in vitro, T&H = TEWL and hydration.   
=negative effect, =no or mixed positive/no effect, =significantly positive effect.  




5.2 Assumptions, limitations and delimitations 
This review was initiated due to the desire to explore the question of what moisturisers to use 
for burn patients. However, to ensure that maximum study outcome data was collected, the 
assumption was made that scars that arise from burn injury are similar to those that arise from 
trauma or surgery. This is due to the anatomical basis for the scarring in that hypertrophic 
scars are arising from trauma to the dermis in both instances, regardless of the cause, thereby 
justifying this assumption.  
A limitation of this review is the quality of outcomes measured in the literature. It is only 
recently that researchers have used instrumentation to measure scar outcomes compared to 
using scar scales and observer rated VASs or questionnaires. This review only identified one 
study that utilised instrumentation to objectively measure outcomes.19 Instrumentation such 
as a cutometer to measure skin elasticity, evaporimeters to measure TEWL, and colorimeters 
to measure the colour are needed to provide studies with valid, objective data. The scar scales 
may provide reasonable intra-rater reliability and measures of change over time but may have 
questionable inter-rater reliability. Subjective scar scales and VASs have been popular as 
they are easily utilised by clinicians as part of their usual clinical workload and most studies 
are performed by a researcher who is also attempting to juggle a clinical and research 
portfolio. The exception is in vitro studies where the measurements are quite robust and 
quantitative but in vitro studies may not necessarily transfer over to clinical practice.  
A limitation of the results of this systematic review may be that research that is typically 
conducted in this field is predominantly conducted on specialised ingredients within 
moisturisers but there is limited findings on the low cost, over the counter moisturisers. These 
specialised ingredients are usually drugs that can have some significant effects on cellular 
processes such as the immune modulators (imiquimod, Tacrolimus ointment and Doxepin) 
and the effectors of collagen synthesis or topical steroids (Putrescine/Fibrostat, Clobetasol 
proprionate 0.05%w/w / Dermovate, Aristocort® 0.1%). Some of the moisturisers included in 
this review have potentially less toxic effects but are exceptionally expensive (high cost, over 
the counter group) compared to the basic moisturisers. The cost to the consumer of these 
creams would prohibit their use on larger scars and by those with limited finances and would 
therefore only be of interest to those undergoing small cosmetic surgeries.  
The moisturisers that may be considered basic moisturisers due to their cost and non-toxic 
ingredients that appeared in this systematic review were outlined in the “low cost, over the 
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counter” category. These moisturisers were often not the primary focus of the study being 
conducted but were used as control moisturisers. Although a consumer with large areas of 
scarring (such as burns patients) use arguably the greatest volume of moisturisers for their 
scars there is limited data available on their effectiveness.  
Since the searches were completed in September 2016 there may be new articles of relevance 
that have been published. An updated search has not been performed but an article was 
identified in the Australian Hand Therapy Association newsletter which identified a 
systematic review and other articles on vitamin E creams.120 The systematic review that this 
review identified found some studies that the current systematic review had not identified.121 
On closer examination of PubMed’s MeSH headings, this was due to the search term ‘topical 
application’ not being utilised in the current systematic review. It is unknown if there are 
other broader search terms that could have identified articles for inclusion. Another limitation 
related to the searches is that searches were limited to English language only, thereby 
excluding potentially valuable studies in other languages.  
To ensure quality and depth of data to from which conclusions can be drawn, only complete 
studies were included in this systematic review. This potentially could be a limitation on the 
results of the review as there were many studies that were retrieved that were abstracts only, 
usually from conference proceedings (see Appendix 3). These may have contained valuable 
data and further knowledge. Despite contacting authors, no further information was retrieved.  
 
5.3  Implications for research 
Of note in the articles sourced for this systematic review, there was a lack of robust 
measurements of scars. Scar scales provide little objective detail with scales often only 
spanning a scale of 0 to 4. Although patient perspectives are important for clinical outcomes, 
patient rated scales are also quite subjective. Instrumentation to measure scar parameters are 
required to accurately measure scar progress. Measurement tools such as 
spectrophotometry/colorimetry (colour), tissue tonometry (pliability),76 standardised digital 
imaging and spectral modelling (vascularity and melanin),77 electrical hygrometers such as 
the Tewameter® (TEWL), to name a few, are required to accurately and objectively measure 
scars. There was only one study in this systematic review that utilised a Tewameter® to 
measure TEWL and a Corneometer® to measure hydration of the stratum corneum.19 What is 
needed are more studies reporting on the effects of the most popular and widely available 
moisturisers on TEWL and hydration of scars or scar models. De Paepe et al.(2015)125 
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reported in their study the effect of petrolatum on TEWL and hydration and referred to a 
number of other studies that did the same. However, in their study, the application was to 
normal skin.125 It is unknown whether this data can be translated to scars that have obvious 
altered characteristics to normal skin. 
In the selection of subjects, scars need to be the same in type (e.g. linear, hypertrophic or 
keloid), location, and age or stage of development, and this needs to be clearly documented in 
the study. An alternative to choosing appropriate scars would be to utilise a scar model such 
as the tape stripping method employed by Hoeksema et al.(2013)19 as they reported that this 
resulted in more reliable TEWL readings compared to taking TEWL readings from scars.  
Linear scars are not a useful scar type for determining the effectiveness of scar management 
techniques. These have been observed clinically to be non-problematic with minimal to low 
incidences of hypertrophy and contracture. Results of studies employing subjects with linear 
scars are treated with caution as these scars often produce favourable scar scores without 
intervention. These procedures result in a linear wound where normal skin closely 
approximates normal skin on the other side of the wound. Since wound closure and 
epithelialisation occurs within 10-14 days, it does not stimulate hypertrophic scar 
formation.11, 12 Some studies retrieved in this systematic review contained a mix of keloid and 
hypertrophic scars. Ideally, they should not be combined. The understanding of the 
underlying mechanisms of both types of scars is now more developed and it would be 
unlikely that a study would combine them in future.  
Although statistical significance is important, research should provide comment on clinical 
significance of results. Scar scales are often totalled or combined when there is no clear basis 
for doing so. Total scores that then differ by a few points are reported as a statistically 
significant result and researchers have been implying this as clinically significant in their 
conclusions. If scar scales are to be used, then interpretation of their results and what 
constitutes a clinically relevant difference should be clarified.  
The methodology of the studies also needs to be carefully considered when performing 
research. Studies should be adequately powered and have an appropriate comparison group 
which is as similar as possible to the treatment group. They should also be randomised where 





Problematic scars such as keloid and hypertrophic scars are commonly an unpleasant 
cosmetic and functional side effect from burns, trauma and surgery. Moisturising is one of the 
standard scar management techniques recommended by health professionals.  
Of the six prescription moisturisers, Imiquimod, Tacrolimus, Dermovate and Aristocort® are 
not recommended for scars. Doxepin may be useful to control itch and topical putrescine may 
assist in reducing scar parameters. High cost, over the counter moisturisers that cannot be 
recommended with any certainty are Bio-Oil®, Wubeizei, Lumiere Bio-Restorative Eye 
Cream, Mederma®, and Scarguard®. Keratin gel may be useful to reduce scar parameters 
and Mugwort lotion for itch. More confident recommendations can be made for Tretinoin 
cream/vitamin A or scar parameters, Provase® for itch and Alhydran for improving TEWL 
and hydration.   
No basic moisturisers stood out that can be recommended with great confidence. Except for 
vitamin E containing moisturisers, there were no studies looking primarily at their outcomes, 
rather observations were made when they were used as a control moisturiser. However, they 
were low cost and had minimal adverse events and should not be ruled out, as yet, to have an 
effect. The exceptions were aqueous cream and vitamin E containing moisturisers which 
increased TEWL and adverse events, respectively.  
Recommendations for research include careful selection of subjects and especially outcome 
measures. In particular, measurement of TEWL and hydration, and use of instrumentation as 
opposed to scar scales and other scales or questionnaires would result in more reliable 
research that could confidently be transferred into clinical practice. Many patients with scars 
want recommendations from clinicians on what moisturiser they can easily purchase and the 
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Appendix 2: Critical appraisal tools 
These are the critical appraisal tools that were used in this systematic review and are 
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